INDEX TO PROCEEDINGS SUPPLEMENTS TO VOLUMES 81, 82 and 83 AUTHOR INDEX

ABBCT, W.M. & STRANGE, P.G. Use of ANIS, N.A., BERRY, S.C., BURTON, N.R., immobilised lectins for partial DAWKINS, S.L. & LODGE, D. Effects purification of D2 dopamine receptors, of psychotomimetic benzomorphans on 113P responses of cat spinal neurones to ABRAHAMSEN, J. & NE ERGAARD, O.A. excitatory amino acids and acetyl- Accumulation of [ H]-adrenaline by choline, 196P rabbit isolated aorta, 327P ANWYL, R. & ROWAN, M.J. Antagonism ADAMS, M. & MARSHALL, I. Chronic of inhibitory but not excitatory infusions of idazoxan and desmeth- effects of 5-hydroxytryptamine in the ylimipramine on cr2-receptor control rat hippocampal slice, 273P of noradrenaline release, 316P APPLEYARD, M.E., GREEN, A.R. & SMITH, ADHAM, N. & TEMPLETON, D. The effect A.D. Regional acetylcholinesterase of parasympathetic denervation on activity in rat brain following a [ H]-QNB binding in the rat parotid convulsion, 248P gland, 323P ARBILLA, S., BAUD, P., CANTRILL, R. & AL-GADI, M. & HILL, S.J. The effect LANGER, S.Z. Endogenous phenolamines: of cimetidine and mepyramine on do they have a direct postsynaptic histamine stimulated cAMP accumulation action on dopamine receptors in the in rabbit cerebral cortical slices, central nervous system? 252P 278P ARBILLA, S., DENNIS, T., LANGER, S.Z., ALABASTER, V.A. & PETERS, C.J. Pre- NIDDAM, R. & SCATTON, B. Pretreatment and post-junctional 62-adrenoceptors with reperpine does not modify the can be differentially antagonised, amphetamine induced release of 163P endogenous dopamine in striatal ALDERSON, E. see MARSHALL, E.F., 351P slices, 249P ALLELY, M. & UNGAR, A. The effect ARCHER, D.R. & LYLES, G.A. Amine of thyroid state on the responses oxidase activities in dissociated of conscious dogs to propranolol, cell fractions from rat skeletal sotalol and nadolol, 7P muscle, 421P ALPS, B.J., BROWN, C.M., CALDER, C. ARENSON, M.S. & NISTRI, A. Intracellul- & KILPATRICK, A.T. Brain dopamine ar studies of the action of K+ channel levels following experimental cerebral blockers on frog motoneuronal respons- ischaemia, 449P es to excitatory amino acids, 152P ANDERSON, D.R., CABEROS, L., FENN, C.G. ARMSTRONG, R.A., JONES, R.L., & LITTLETON, J.M. Reduced platelet PEESAPATI, V., WILL, S.G. & WILSON function in rats treated chronically N.H. Efect of the thromboxane recept- with ethanol, 322P or antagonist EP 092 on the early ANDERSON, R.A. & MITCHELL, R. Benzo- phase of endotoxin shock in the sheep, diazepines potentiate the effect of 72P muscimol on prolactin secretion ARR, S.M., COOPER,W.D., CRUTCHER, E.C. in vitro, 343P & QUINN, P.J. The effects of pro- ANDERSON, S., LLEWELLYN, K.D., SNOOK, G. pranolol and timolol on rat heart & WILSON, J.F. Penetration of 6d- mitochondrial function, 223P melanocyte-stimulating hormone through ARUNDEL, P.A., BILSKI, A.J.T. & THOMSON the blood-brain barrier in the rat, D.S. A new photometric method for 106P quantifying erythema induced by UV- ANGELL, D., CLOUGH, D.P., HATTON, R. B irradiation, 192P & ROBERTS, A.J. The effect of ATTERWILL, C.K. Effect of thyroid enalapril and bilateral nephrectomy status on the different forms of on sympathetic function in normo- Na , K -ATPase in immature and mature tensive rats, 339P rat brain, 450P ANGELO-KHATTAR, M., JOSEPH, L., NILSSON, T. & THULESIUS, 0. The effect of indomethacin on ureteral motility, 230P ATTERWILL, C.K. & NUTT, D.J. Thyroid 5-HT uptake in rat brain by molecules hormones do not alter rat brain benzo- possessing long alkyl side chains, diazepine receptor function in vivo, 425P 194P BARBER, D.J., BARBOUR-McMULLEN, J. & ATTERWILL, C.K., NICHOLLS, J. & PRINCE, COOPER, S.J. Opiate receptor A.K. Cholinergic function in develop- antagonists attenuate sweetened milk ing rat brain cell cultures: effects consumption in male and female rats of thyroid hormone, 32P of the Roman strains, 291P AZAMI, J., FOZARD, J.R., ROUND, A.A. BARBER, H.E., PETRIE, J.C. & SMITH, K.J. & WALLIS, D.I. Selective blockade by A comparison of cimetidine and MDL 72222 of the depolarizing action ranitidine: effect on liver blood of 5-hydroxytryptamine on vagal flow, 93P primary afferents, 129P BARBOUR-McMULLEN, J. see BARBER, D.J., 291P BACK, D.J. & RIVIERE, J.H. Inhibition BARNETT, D.B., COOK, N. & NAHORSKI, of drug metabolism by mefloquine, S.R. Characterisation of the binding 433P of 125 l-(-)pindolol to human platelet BACK,D.J., SUTCLIFFE, F. & TJIA, J.F. -adrenoceptors, 160P Tolbutamide is a good model drug for BARNETT, D.B., NAHORSKI, S.R. & 3 the study of enzyme induction and RICHARDSON, A. Modulation of [ H]- enzyme inhibition in the rat, 149P dihydroergocryptine and [ H]-yohimbine BAILEY, S.J. & JORDAN, C.C. Loss of binding sites on human platelets activity of tachykinins in smooth during the menstrual cycle, 159P muscle: relevance to potency estimates BARR, J, & SKETT, P. The role of in vitro, 61P cytochrome P-450, NADPH-cytochrome BAKER, S., FLOCKHART, I.R., MARSHALL, P-450 reductase and lipids in sex I., TULLOCH, I.F. & WALTER, D.S. differences in hepatic drug metabol- Locus coeruleus lesions abolish feed- ism, 396P back of noradrenaline onto 'presynap- BARR, R.M., FRANCIS, D.M., GREAVES, M.W. tic' - 2-adrenoceptors in rat cerebral & KOZUKA, T. Prostaglandin D 2 release cortex, 49P by guinea-pig skin during in vitro BALFOUR, D.J.K. & COPLAND, A.M. anaphylaxis, 99P Effects of diazepam on the concent- BARRETT, K.E., PEARCE, F.L. & THOMPSON, ration and biosynthesis of 5- hydrox- H. Histamine secretion from mast ytryptamine in rat brain, 354P cells stimulated with nerve growth BALFOUR, D.J.K. & IYANIWURA, T.T. factor, 90P Studies on the effects of d-ampheta- BATES, R.F.L., BUCKLEY, G.A. & MCARDLE, mine on brain 5-HT and plasma cortico- C.A. Comparison of the antiociceptive sterone in stressed rats, 457P effects of centrally administered - - - The effects of d- amphetamine calcitonins and calcitonin gene- on brain 5-hydroxytryptamine and related peptide, 295P plasma corticosterone in unstressed - - - Pressor effect of centrally rats, 456P administered salmon calcitonin (sCT), BALFOUR, D.J.K., BATTIG, K., FITZGERALD, 408P R. & OETTINGER, R. The effects of BATES, R.F.L., BUCKLEY, G.A., EGLEN, nicotine on the behaviour of two R.M. & MCARDLE, C.A. Possible strains of rats in a combined maze- mechanisms of action of calcitonin in open field, 376P haemorrhagic hypotension, 157P, BALFOUR, D.J.K., LAMBERT, J.J., LYLES, BATTIG, K. see BALFOUR, D.J.K., 376P G.A., OGG, G.D. & STEVENSON, I.H. BAUD, P. see ARBILLA, S., 252P Basic self-assessment tutorials in BEATTIE, D.E., MORONEY, M-A. & WYLLIE, pharmacology, 463P M.G. Interrelationship between Na BALL, H.A. & PARRATT, J.R. Effects K -ATPase and K -ATPase in gastric of a new thromboxane receptor antag- mucosa, 398P onist, AH23848, on the acute cardio- BENKELFAT, C., GALZIN, A.M., LANGER, pulmonary responses to E. Coli endo- S.Z., LOO, H., POIRIER, M.F., toxin in cats, 379P SCHOEMAKER, H., SECHTER, D., SEGONZAC, BANSAL, S.J., BRECKENRIDGE, R.J., A. & ZARIFIAN, E. [ H]-imipramine IVERSEN, L.L., SUCKLING, C.J., binding in human blood platelets: WATLING, K.J. & WILLIAMS, L.C. changes after chronic chlorimipramine Non-selective inhibition of GABA and treatment, 352P BENNETT, G.W., LIGHTON, C. & MARSDEN BERRY, S.C. see ANIS, N.A., 196P C.A. The effects of 5,7-dihidroxy- BEY, P., FOZARD,J., MCDONALD, I., tryptamine and p-chlorophenylaline PALFREYMAN, M.G. & ZREIKA, M. MDL on the ex vivo release of thyro- 72145: a potent and selective trophin releasing hormone, 267P inhibitor of MAO type B, 50P BENNETT, P.N., NOTARIANNI, L.J. & PATEL, BILL, D.J. & STEPHENS, R.J. Clonidine D.K. Capacity limited metabolism of reverses reserpine-induced hypothermia acetylsalicyclic acid in the rat, in the mouse via activation of central 228P post-synaptic .12-adrenoceptors? 372P BENNETT, P.N., NOTARIANNI, L.J. & BILSKI, A.J.T. see ARUNDEL, P.A., 192P WORLOCK, A.J. Metabolism of ligno- BIRCH, N.J., COLEMAN, I.P.L., HILBURN, caine in the perfused rat liver M.E. & KARIM, A.R. Factors affecting in situ following flow variations lithium absorption in the rat small in hepatic artery and portal vein, intestine, 158P 403P BIZIERE, K., GUEUDET, C., KAN, J.P., BENNETT, T. & GARDINER, S.M. Antagonism SOUILHAC, J. & WORMS, P. Atypical of the vardiovascular action of vaso- dopaminergic profile of minaprine, a pressin lowers blood pressure in new antidepressant drug, 51P isolated rats, 320P BLACKBURN, T.P., BOWERY, N.G., COX, B., BENNETT, T., GARDINER, S.M. & WINN, HUDSON, A.L., MARTIN, D. & PRICE, G.W. M.J. Factors involved in BP recovery Lesion of the dorsal raphe nucleus following c(- adrenoceptor antagonism: increases the nigral concentration sFudies in Long Evans and Brattleboro of 5-HT1 receptors, 203P rats, 84P BLACKMAN, A. & WOODS, A.M. A mouse - - - The influence of vaso-pressin in vivo model to detect dual on BP following A- adrenoceptor inhibitors of arachidonic acid antagonism, 217P metabolism, 335P BENTLEY, A.M. & OSBORNE, N.N. BLACKHAM, A., NORRIS, A.A. & WOODS, A.M. Feasibility study of a serotonin Modulation of arachidonic acid radioimmunoassay kit assembled from metabolism in immune models of cell commercially available materials, infiltration, 98P 274P BLAIR, I.A. HUGGETT, A. & ORCHARD, M.A. BERN, H.A., BOTTING, J.H., GIBSON,A. & Prostaglandin synthetase catalyzed GINSBURG, M. The effect of some activation of paracetamol by human neuropeptides on tone of the mouse platelets, 67P anococcygeus muscle, 104P BLOWER, P.R. & BOWRING, N.E. The effect BERRIDGE, T.L., DETTMAR, P.W., DOXEY, of acid perfusion and VIP infusion on J.C., GADIE, B., LORD, J.A.H., ROACH, the neutralising capacity of the duo- A.G., TULLOCH, I.F. & VIRDEE, N.K. denum of the anaesthetised rat, 105P Agonist and antagonist properties BLURTON, P., WOOD, M.D., & WYLLIE, M.G. of RX 801074 at peripheral and central The analgesic meptazinol displays a .'2-adrenoceptors in the rat, 179P selective interaction at the opioid BERRIDGE, T.L., DOXEY, J.C., ROACH, pu-site, 59P A.G., STRACHAN, D.A. & VIRDEE, N.K. BLURTON, P.A., BROADHURST, A.M., CROSS, Antagonist effects of idazoxan and J.A., ENNIS, C., WOOD, M.D. & WYLLIE, yohimbine against several 1-adreno- M.G. Panuramine: a selective inhibitor ceptor agonists in pithed rats, 86P of 5-HT uptake, 36P BERRIDGE, T.L., ROACH, A.G., STRACHAN, BOAKES, R.J., TURNER, J.D. & VIRMANI, D.A. & VIRDEE, N.K. Selectivities of M.A. Effects of putative anion trans- idazoxan, WY 26703 and yohimbine for port inhibitors on the release of 5- prejunctional c)2-adrenoceptors in hydroxytryptamine induced by low rats and dogs, 315P chloride superfusion, 349P BERRY, C.N. & HOULT, J.R.S. Prosta- - - - Modulation by convulsants of the glandin release from the rabbit release of 5-hydroxytryptamine induced isolated perfused kidney and its by low chloride concentrations, 256P inhibition by dexamethasone, 68P BOARDER, M.R. & MCARDLE,W. (Introduced - - - Stimulators and inhibitors of by NAHORSKI, S.R.) Release of nor- prostacyclin formation identified by adrenaline and adrenaline from using intact fragments of rat caecum, perfused cultured bovine adrenal 69P chromaffin cells, 363P BODEN, P., DUCE, I.R. & USHERWOOD, - - - Persistent motor change P.N.R. Activation-induced post- following the unilateral infusion of synaptic block of insect nerve-muscle MPTP into the striatum of rat brain, transmission by a low molecular weight 395P fraction of spider venom, 221P BRADBURY, A.J., COSTALL, B., KELLY, BOGAERT, M.G., DUPONT, A.G. & E.M. & NAYLOR, R.J. Control of LEFEBVRE, R.A. Effect of apomorphine fore-brain dopamine function from on neurogenic vasoconstriction in the the midbrain, 308P isolated autoperfused hindquarters BRADBURY, A.J., GIDDINGS, R.E. & of the rat, 410P SMITH, J.A. The effect of DL-1- BOJANIC, D., JANSEN, J.D., NAHORSKI, monofluoromethyldopa on rat pineal, S.R., ZAAGSMA, J. Atypical nature hypothalamic and cortical function, of rat adipocyte /?-adrenoceptors: 139P evidence from lipolysis and cAMP BRADLEY, J.B., HUMPHREY, P.P.A. & production, 4P WILLIAMS, R.H. Monoamine oxidase BOKISCH, A.J., KROGSGAARD-LARSEN, P. activity affects antagonism of & WALKER, R.J. The action of Y-amino- responses to tryptamine but not to acid (GABA) on identified central 5-hydroxytryptamine in rat caudal neurones of Helix aspersa, 125P artery, 210P BOLT, G.R. & SAXENA, P.R. Character- BRADLEY, P.B., JONES, H. & ROBERTS, F. ization of the hypotensive mechanism Histamine potentiates the effects of ketanserin in conscious renal of excitatory amino acids on hypertensive rabbits, 227P quiescent neurones in the rat BOOBIS, A.R. & GULAID, A.A. Chroma- medulla, 195P tographic resolution and stereo- BRADSHAW, C.M., MORLEY, M.J & selective disposition of acebutolol SZABADI, E. Effects of pimozide on and diacetolol in dog and man, 89P operant performance in variable- BORNKOWSKI, K.R. & PORTER, M. interval schedules: failure to Potentiation of noradrenaline-induced obtain support for the anhedonia vasoconstriction by (-) isoprenaline hypothesis, 117P in SHR mesenteric arteries, 16P BRADSHAW, C.M., SHERIDAN, R.D. & BORKOWSKI, K.R. & QUINN, P. A /1- SZABADI, E. An investigation of the adrenoceptor involvement in the deve- specificity of prazosin as an01- lopment of spontaneous hypertension adrenoceptor antagonist on single in rats, 222P cortical neurones, 47P BORKOWSKI, K.R., COLLIS, M.G. & QUINN, BRAMMER, N.T., BUCKLEY, G.A. & P. Adrenaline enhances vasoconstric- MIREYLEES, S.E. Inhibition of tor responses evoked by adrenergic dopamine uptake in rat striatal nerve stimulation in the rat isolated slices by phenylethylamine perfused kidney, 20P derivatives, 112P BOTTING, J.H. see BERN, H.A., 104P BRASWELL, L.M., DODSON, B.A. & MILLER, BOWERY, N.G. see BLACKBURN, T.P., K.W. Allosteric and non-specific 203P interactions of barbiturates with BOWRING, N.E. see BLOWER, P.R., 105P the acetylcholine receptor from BOYCE, S., JENNER, P., KELLY, E., Torpedo, 30P MARSDEN, C.D. & REAVILL, C. Chronic BRECKENRIDGE, A.M., COLEMAN, M.D., administration of N-methyl-1,2,5,6- EDWARDS, G., HOWELLS, R.E. & tetrahydro-pyridine to rats is not MIHALY, G.W. Micro analytical toxic to striatal dopamine neurones, HPLC method for the determination of 194P pyrimethamine and its 3-N-oxide BRADBURY, A.J., COSTALL, B., DOMENEY, metabolite in biological fluids, A.M. & NAYLOR, R.J. The behavioural 275P and biochemical consequences of BRECKENRIDGE, A.M., COLEMAN, M.D., dopamine infusion into the frontal EDWARDS, G., HOWELLS, R.E., MIHALY, cortex of rat brain, 307P G.W. & WARD, S.A. The pharma- BRADBURY, A.J., COSTALL, B., DOMENEY, cokinetics and tissue localisation a.m., JENNER, P., MARSDEN, C.D. & of pyremethamine in the mouse: NAYLOR, R.J. Behavioural and bio- effect of dose size, 399P chemical consequences of bilateral infusion of MPTP into rat forebrain, 393P BRECKENRIDGE, J.R. see BANSAL, S.J. BRODDE, O.-E. & O'HARA, N. Affinity of 425P bucindolol to d%- and f-adrenoceptor BRIGHT, J.E., KENNY, T. & MARRS, T.C. subtypes as evaluated by radio-ligand The induction of methaemoglobin by binding studies, 173P hydroxyaminopropiophenone, 279P BRODDE, O.-E., O'HARA, N., REIDEMEISTER, BRILEY, M. & MORET, C. Inhibitory J. Chr., ROHM, N. & ZERKOWSKI, H.-R. effect of dihydroergocristine on 5HT Properties of human cardiac /-adreno- release from rat hypothalamic slices, ceptor coupled adenylate cyclase, 6P 353P BROWN, C.L., JONES, B.J., MARTIN, I.L. BRILEY, M., CARILLA, E. & ROGER, A. & OAKLEY, N.R. Efficacy at the benzo- Inhibitory effect of permixon on diazepine receptor: in vivo studies testerone 5o(-reductase activity of the with pyrazoloquinolinones, 236P rat ventral prostate, 401P BROWN, C.M. see ALPS, B.J., 449P BRILEY, M., CHARVERON, M., COURET, E. & BROWN, C.M., DUNCAN, G.P., MCKENNIFF, STENGER, A. Tofisopam enhances the M., PATMORE, L. & WHITING, R.L. anti-convulsant activity of diazepam /3-adrenoceptor binding characteristics against some, but not all, convulsive of cultured human cardiac cells, 416P agents, 300P BROWN, C.M., DYE, A.C. & WHITING, R.L. BRINE, J.M., KEELING, D.J., POAT, J.A., Comparison of the rate of cerebro- SMITH, I.R. & WOODRUFF, G.N. Onto- cortical /?-adrenoceptor 'down regula- genesis of histamine, histamine tion' following RS-21361 and des- decarboxylase and histamine N-methyl- methylimipramine, 310P transferase in chick brain, 174P BROWN, E., KENDALL, D.A. & NAHORSKI, BRISTOW, D.R. & WATLING, K.J. GABAB S.R. The relationship between agonist receptor stimulation increases vaso- occupation of cerebral ckI-adrenocep- active intestinal peptide activated tors and phosphoinositide hydrolysis, cyclic AMP accumulation in slices of 154P rat cerebral cortex, 359P BROWN, F. & CAMPBELL, W. Comparison of BRITTAIN, R.T., COLEMAN, R.A., the effects of 3-PPP and its COLLINGTON, E.W., HALLETT, P., enantiomers on emesis, plasma HUMPHREY, P.P.A., KENNEDY, I., LUMLEY, prolactin levels and CNS dopamine P., SHELDRICK, R.L.G. & WALLIS, C.J. turnover, 45P AH 23848: a potent, selective throm- boxane receptor blocking drug, 377P BROWN, F., CAMPBELL, W., MITCHELL, P. & BROADHURST, A.B., HORTON, R.W., RANDALL, K. Dopamine autoreceptor PRESTWICH, S.A. & WYLLIE, M.G. agonism defined by inhibition of Examination of the interaction of L-dopa syntheses and spiperone- OQ-antagonists with GABA-recognition sensitive exploratory locomotion, sites in rat brain membranes, 448P 305P BROADHURST, A.M. see BLURTON, P.A., BROWN, M.J. & HARLAND, D. Effect of 36P central and peripheral administration BROADHURST, A.M., WOOD, M.D., & of RX 781094 on BP and plasma nor- WYLLIE, M.G. The association between adrenaline responses to clonidine serotonin uptake, and antidepressant in rats, 8P binding sites, 37P BROWN, R.A., FARMER, J.B., HALL, J., BROADLEY, K.J., CHESS-WILLIAMS, R.G. HUMPHRIES, R.G., O'CONNOR, S.E. & & GRASSBY, P.F. Responses mediated SMITH, G.W. FPL 60278, a novel via / but not fL-adrenoceptors agonist at peripheral dopamine re- exhibit supersensitivity after 6- ceptors and 42-adrenoceptors: cardio- hydroxydopamine pretreatment, 224P vascular effects in the dog, lOP BROADLEY, K.J., CHESS-WILLIAMS, R.G. BROWN, R.A., FARMER, J.B., HALL, J.C. & SHERIDAN, D.J. Do guinea-pig KASPRZAK, L., O'CONNOR, S.E., SMITH, ventricular myocardial 'X-adrenoceptors G.W. & YOUNG, A. FPL 60278 exist? 215P (dopexamine): actions at pre and post- BROADLEY, K.J., CHESS-WILLIAMS, R.G., junctional dopamine receptors and at GRASSBY, P.F. & HAWTHORN, M.H. d- and Pi- adrenoceptors, 120P Examination of reserpine- and hypo- thermia-induced supersensitivity to /3-adrenoceptor agonists by use of forskolin, 329P BROWNE, J.L. & PILCHER, C.W.T. Effects BURKE, M.D., KILGOUR, C. & PERTWEE, R.G. of housing density on nociception Potent but selective inhibition of of heat and pressure and the hyper- cytochrome P-450 by cannabidiol, algesic actions of naloxone and Mr 445P 1452, 299P BURTON, N.R. see ANIS, N.A., 196P BRUNDISH, D.E., HIRST, B.H., KENDALL- BUSCHMANS, E., HEARSE, D.J. & MANNING, TAYLOR, P., SNELL, C.R., WEIGHTMAN, A.S. Forskolin and inotropic activity D.R. & WHITFORD, C.A. Character- in the rat and guinea-pig isolated isation of two high affinity binding heart: modification by the - adreno- sites for [3H] somatostatin in rat ceptor? 85P brain, 369P BUTCHER, S.P., COLLINS, J.F. & ROBERTS, BRYDON, L.J., DRUMMOND, A.H., P.J. DL-[3H]-2-amino-4-phosphono- KIRKPATRICK, K.A., MACINTYRE, D.E., butyrate labels postsynaptic excitat- POLLOCK, W.K. & SHAW, ARM. Agonist- ory amino acid receptors in rat induced insoitol phospholipid turnover striatum, 251P and calcium flux in human platelet - - - Calcium ions regulate excitatory activation, 187P amino acid receptors labelled with BUCKETT, W.R. & DIGGORY, G.L. The anti- DL-[3H]-2-amino4-phosphonobutyrate, depressant dothiepin induces down- 135P regulation of cortical 5-HT2 receptors after subchronic oral treatment in CABEROS, L. see ANDERSON, D.R., 322P the rat, 270P CALDER, C. see ALPS, B.J., 449P BUCKETT, W.R. & LUSCOMBE, G.P. Chronic CALDERWOOD, A., SKINGLE, M. & TYERS, hydrocortisone does not alter the M.B. A microcomputer system for the response of mice in catecholamine- collection and analysis of opiate dependent behavioural models, 306P side-effect data, 347P - - - Chronic hydrocortisone induces CALDWELL, J., HORNER, M.W., HOUGHTON, central serotonergic supersensitivity E., MOSS, M.S., SMITH, P.B.W. & SMITH, without affecting a behavioural para- R.L. the disposition of phenylbuta- digm for depression, 132P zone in the horse, 402P - - - Depletion of striatal dopamine CALVETE, J.A., HAYES, R.J. & THOM, S. by MPTP does not alter spontaneous (Introduced by OATES, N.S.) Evidence or dopamine-dependent behaviour in for the occurrence of histamine Hi albino or pigmented mice, 427P receptors in human vas deferens, 441P BUCKETT, W.R., DIGGORY, G.L. & LUSCOMBE, CALVETE, J.A., HAYES, R.J., OATES, G.P. In albino and pigmented mice N.S, SEVER, P.S. & THOM, S. is MPTP selectively depletes dopamine and -a adrenoceptor responses in from striatal and limbic areas but human isolated arteries, 364P not from hypothalamus, 394P CAMERON, H.A., EPSTEIN, P.M., LAMBERT, BUCKINGHAM, R.E. Implied involvement of J.J. & LYLES, G.A. Properties of prostaglandins in the anti-hypertensive [3H]-nitrendipine binding to homo- response to propranolol in spontan- genates of chick heart, 444p eously hypertensive rats (SHR), 97P CAMPBELL, W. see BROWN, F., 45P BUCKLEY, G.A. see BATES, R.F.L., 157P - - - see BROWN, F., 305P - - - see BATES, R.F.L., 295P CANDY,m J.M., COURT, J.A., PERRY, R.H. - - - see BATES,,R.F.L., 408P & SMITH, C.J. Carbachol-stimulated - - - see BRAMMER, N.T., 112P phosphatidylinositol hydrolysis in BULL, D.R. & DREW, G.M. How important the cerebral cortex after freezing is the presynaptic effect of angio- and post mortem delay, 356P tensin II in modulating pressor CANDY, J.M., PERRY, R.H. & THOMPSON, responses to sympathetic nerve J.E. Lack of muscarinic binding sites stimulation? 319P on cholinergic neurones in the human BULLOCK, G.R., CHRISTMAS, S.E., JASANI, basal forebrain, 62P M.K., JAYSON, M.I.V., KEMMENOE, B.H. CANDY, J.M., SNELL, C.R. & SNELL, P.H. & SIBBONS, P.D. Lymphocytes, Autoradiographic localisation of inflammation and fibrin in a rat nicotinamide adenine dinucleotide cardiac allograft rejection model, binding sites in the rat brain, 311P 92P CANE, A.K., EDWARDS, D.J., HAMMOND, M.D. CHURCH, M.K., HOLGATE, S.T. & HUGHES, & TAYLOR, W.A. Evaluation of cellular P.J. Inhibition and potentiation of infiltration in a guinea-pig model immunological histamine release from of pulmonary hypersensitivity, 186P human lung mast cells by adenosine, CA4IFIELD, P., CORUZZI, G., CURWAIN, B. & 76P RUNDELL, T. The action of FPL 52694 - - - Inhibition of histamine release and disodium cromoglycate on gastric from human basophils by "P-site" acid secretion by rat isolated stomach, inhibitors of adenylate cyclase, 77P 156P CHURCH, M.K., HOLGATE, S.T. & KIM, Y-Y. CANTRILL, R. see ARBILLA, S., 252P Inhibition of histamine release from CARILLA, E. see BRILEY, M., 401P human mast cells by nifedipine and CARMEN, see CAVERO, I., 14P nicardipine, 264P CAVERO, I. & SABATIER, J. Pharmacolog- CLAGUE, R.U., EGLEN, R.M., STRACHAN, ical interventions to antagonize A.C. & WHITING, R.L. Muscarinic adverse electro-cardiographic effects antagonist properties of secoverine of high doses of diltiazem in conscious and atropine on guinea-pig ileum and dogs, 147P atria in vitro, 345P CAVERO, I., GALZIN, A.-M., LANGER, CLAGUE, R.U., KILPATRICK, A.T. & S.Z., LEFEVRE-BORG, F., MANOURY, Ph. WHITING, R.L. iv,-adrenoceptor antag- & PIMOULE, CARMEN. Alfuzosin onists: a new approach to the treat- (SL 77 499), a new antihypertensive ment of hyperglycaemia, 436P agent with a peripheral site of action: CLARK, E.R. & ROBINSON, S.P. Effect 11. in vitro pharmacological studies, of pregnant mare serum gonadotrophin 14P on mammary tumours induced by 7,12- CAVERO, I., GROSSET, A. & LEFEBRE-BORG, dimenthylbenz a anthracene (DMBA) F. Protective effects of diltiazem in the rat, 229P against adrenaline and calcium evoked CLARKE, B. & PATMORE, L. (Introduced dysrhythmias, 146P by WHITING, R.L.) Differential CAVERO, I., LEFEVRE-BORG, F. & MANOURY, effects of ryanodine on calcium entry Ph. Alfuzosin (sl 77 499), a new and contraction in cardiac muscle, antihypertensive agent with a peri- 438P pheral site of action: 1. in vivo CLARKE, B., DUNCAN, G.P., PATMORE, L. pharmacological studies, 13P & WHITING, R.L. Measurement of calcium antagonist potency using CARRUTHERS, B., DAWBARN, D., DE QUIDT, cardiac cell cultures, 365P M., EMSON, P.C., HUNTER, J. & REYNOLDS, CLARKE, B., EGLEN, R.M., PATMORE, L. G.P. Changes in neuropeptide content & WHITING, R.L. Cardioselective of amygdala in schizophrenia, 190P calcium entry blocking properties of CHAMBERLAIN, P.D. & NUNN, B. Measure- a nicardipine metabolite, 437P ment of mouse platelet activity CLARKESON, J.S., MICHEL, A.D. & WHITING, in vivo: dose-related responses to R.L. Effect of pH on the binding collagen, ADP, thrombin, 5-HT and of [3H] - prazosin to rat cerebral u46619, 103P cortex, 375P CHARVERON, M. see BRILEY, M, 300P CLAY, T.P. & THOMPSON, M.A. CHEESBROUGH, K.L., MARSHALL, R.W., Pharmacological modulation of allergen RICHENS, A. & WILSON, J.F. Isopren- induced lung dysfunction using a aline action on tetani of slow modified 'pressure box' plethysmo- contracting skeletal muscle, 336P graphic technique, 234P CHESS-WILLIAMS, R.G. see BROADLEY, CLEGG, L.S. see CHURCH, M.K., 282P K.J., 215P CLEGG, L.S. & LINDUP, W.E. Aggregation - - - see BROADLEY, K.J., 224P of albumin and the inverse dependence - - - see BROADLEY, K.J., 329P of binding constants (n Ka) upon CHRISTMAS, S.E. see BULLOCK, G.R., albumin concentration, 180P 92P CLOUGH, D.P. see ANGELL, D., 339P CHURCH, M.K., CLEGG, L.S. & HOLGATE,S.T. COKER, S.J. & PARRATT, J.R. Antiarrhy- Histamine secretion from human skin thmic activity of the thromboxane slices induced by anti-IgE, calcium antagonist AH23848 during canine ionophore A23187, poly-L-lysine and myocardial ischaemia and reperfusion, compound 48/80, 282P 380P - - - Late administration of nifedipine CORTES, R., PALACIOS, J.M. & PAZOS, A. fails to prevent reperfusion-induced Visualisation of multiple serotonin ventricular fibrillation in anaesthet- receptors in the rat brain by auto- ised greyhounds, 214P radiography, 202P COLEMAN, I.P.L. see BIRCH, N.J., 158P CORUZZI, G. see CANFIELD, P., 156P COLEMAN, M.D. see BRECKENRIDGE, A.M., COSTALL, B. see BRADBURY, A.J., 307P 275P - - - see BRADBURY, A.J., 308P - - - see BRECKENRIDGE, A.M., 399P - - - see BRADBURY, A.J., 393P COLEMAN, R.A. see BRITTAIN, R.T., 377P - - - see BRADBURY, A.J., 395P COLES, D.J., ELLIS, C.E., HOLMES, S.W., COSTALL, B., DOMENEY, A.M. & NAYLOR TRIM, J.L. & WILSON, K.L. The effects R.J. Chronic enhancement of dopamine of glycol solvents in some simple agonist action after intraaccumbens tests for CNS activity, 304P dopamine infusion, 257P COLLETT, A.R., RAND, M.J. & STORY, D.F. COSTALL, B., DOMENEY, A.M.., KELLY, Desensitization of nicotinic-evoked M.E. & NAYLOR, R.J. Selective ability catecholamine release from the rabbit of neurotensin to inhibit a raised adrenal gland, 153P mesolimbic dopamine activity, 46P COLLIER, H.O.J., PLANT, N.T., TUCKER, - - - Specificity of prostaglandin J.F. & VON UEXKULL, A. Inhibition action in the striatum to antagonise with adenosine derivatives of opiate dyskinesias, 358P withdrawal effects, 131P COSTALL, B., ENIOJUKAN, J.F. & NAYLOR, COLLINGTON, E.W. see BRITTAIN, R.T., R.J. D1 and D2 dopamine agonist- 377P antagonist action in the nucleus COLLINS, J.F. see BUTCHER, S.P., 135P accumbens to modify mouse spontaneous - - - see BUTCHER, S.P., 251P climbing behaviour, 115P COLLIS, M.G., see BORKOWSKI, K.R., 20P COSTALL, B., GUNNING, S.J. & NAYLOR,R.J. COLLIS, M.G. & SAVILLE, V.L. An in- Cholinergic-mediated contractions of vestigation of the negative chrono- guinea-pig stomach, gall bladder and tropic effect of adenosine on the bladder; effects of metoclopramide, guinea-pig atrium, 413P BRL20627 and SCH23390, 387P. COMBE, D.M. & GEDDES, C. Effect of - - - The hypothalamic site and mech- oxypertine on dopamine receptor anism of action of metoclopramide to stimulation in the vardiovascular facilitate gastric emptying, 325P system, 415P - - - The hypothalamus as a site of CONNELLY, D.M. & TABERNER, P.V. The action for metoclopramide and clebo- effects of chronic ethanol treatment pride to facilitate gastric emptying, and withdrawal on immuno-reactive 116P serum insulin levels in LACG and COSTALL, B., NAYLOR, R.J. & TAN, C.C.W. diabetogenic C57 BL mice. 397P Apomorphine modifies the volume and COOK, N. see BARNETT, D.B., 160P acid concentration of gastric secre- COOPER, S.J. see BARBER, D.J., 291P tion in the rat via two distinct COOPER, S.J. & DOURISH, C.T. Novelty mechanisms, 337P modifies the stimulant effects of COURET, E. see BRILEY, M., 300P r&-phenylethylamine on locomotion COURT, J.A. see CANDY, J.M., 356P and rearing in the rat, 420P COWEN, P.J., NUTT, D.J. & O'SHAUGHNESSY, COOPER, S.J. & GILBERT, D.B. Dopamine K.M. The anti-convulsant effect of D2 receptor antagonism enhances salt protein synthesis inhibitors, 29P preference in the rat, 258P COWLRICK, I.S. & SHEPPERSON, N.B. COOPER, S.J. & TURKISH, S. Taste and Meptazinol and opiate respiratory the antidipsogenic effects of opiate depression in the conscious rat, 244P receptor antagonists in the thirsty COX, B. see BLACKBURN, T.P., 203P rat, 292P CRESPI, F., KEANE, P.E. & MORRE, M. COOPER, W.D. see ARR, S.M., 223P TRH increases the release of dopamine COPLAND, A.M. see BALFOUR, D.J.K., 354P and serotonin in the nucleus accumbens CORBETT, A.D., KOSTERLITZ, H.W.., and striatum in vivo, 452P MCKNIGHT, A.T. & PATERSON, S.J. CREWE, H.K., LENNARD, M.S., TUCKER, G.T. 3-Funaltrexamine pretreatment of guinea & WOODS, H.F. Inhibition of meto- pig myenteric plexus alters i-agonist prolol oxidation by debrisoquine and sensitivity without affecting opioid other drugs in rat liver microsomes, binding sites, 389P 435P CROSS, J. & WYLLIE, M.G. Evidence DAVIES, C., & STEINBERG, H. Experience for elevated natriuretic hormone mimics amphetamine enhancement of levls in spontaneously hypertensive chlordiazepoxide stimulation in rats, rats, 191P 238P CROSS, J.A. see BLURTON, P.A., 36P DAVIES, J.A. see CUNDEY, J.E., 272P CROSS, J.A., FEKETE, M.I.K., ROTHWELL, DAVIES, J.A. & LEIGHTON, G.E. Effect of N.J., STOCK, M.J & WYLLIE, M.G. cinanserin on the release of glutamate Adrenal corticosteroid-induced alter- from rat cerebellar slices, 271P ations in opioid receptor sensitivity, - - - Efect of 5-hydroxytryptamine on 458P potassium-evoked release of glutamate CROSSMAN, A.R., MITCHELL, I.J., SLATER, from rat cerebellar slices, 133P P., STUART, A.M. & UNWIN, H.P. Pre- DAVIES, J.A., MARSHALL, R.W. & SPARKS, M. paration of primate tissue for receptor A microcomputer system for long-term binding studies from [ H]-2-deoxy- monitoring and analysis of locomotor glucose autoradiography sections, activity, 193P 454P CROUCHER, M.J., DE SARRO, G.B. & DAVIES, W.E. & OWEN, C.D. Amino acid MELDRUM, B.S. Effects of DS 103-282 levels in mice resistant and suscept- on sound-induced seizures and on NMDLA ible to audiogenic seizures (AGS), induced epilepsy in mice, 137P 254P CROUCHER, M.J., JONES, A.W., MELDRUM, DAVIS, E., MCNAMEE, P.M., MARKHAM, A. B.S. & WATKINS, J.C. Relative anti- & SWEETMAN, A.J. Nonsteroidal anti- convulsant activities of two new di- inflammatory agents may activate peptide 'NMDA receptor' antagonists, lipoxygenase by releasing calcium 138P from mitochondria, 440P CRUTCHER, E.C. see ARR, S.M., 223P DAWSON, C. & DEWHURST, D.G. (Introduced CUNDEY, J.E. & DAVIES, J.A. Reduction by HAYLOR, J.) The effect of valproic of neuroleptic-withdrawal induced acid and diazepam on catechol-induced supersensitivity following simultaneous spontaneous convulsions, 451P administration of 5-hydroxy-tryptophan, DAWBARN, D. see CARRUTHERS, B., 190P 272P DAWKINS, S.L. see ANIS, N.A., 196P CUNNINGHAM, J. & NEAL, M. Effect of DE JONGE, A. see VAN DE BERG, G., 9P excitatory amino acids on [3H]-acetyl- DE JONGE, A., MATHY, M.J., THOOLEN, M.J. choline release from the rabbit retina, M.C., TIMMERMANS, P.B.M.W.M., WILFFERT, 31P B. & VAN ZWEITEN, P.A. Inhibition of vasoconstriction to cirazoline in CURWAIN, B., see CANFIELD, P., 156P pithed rats by nifedipine after CURZON, G., DICKINSON, S.L. & KENNETT, phenoxybenzamine, 80P G.A. Behavioural evidence for altered DE JONGE, A., SMIT, G., THOOLEN, M.J.M.C. brain 5-hydroxytryptamine function TIMMERMANS, P.B.M.W.M., WILFFERT, B. following repeated immobilisation in & VAN ZWIETEN, P.A. Inhibitory do- rats, 25P pamine receptors and .t-adrenoceptors - - - Chronic corticosterone decreases on sympathetic neurons innervating the 5-HT dependent in responses the rat, cardiovascular system of the rat, 19P 207P DE PABLOS, I. see MORATINOS, J., 220P CURZON, G., DOURISH, C.T. & HUTSON, P.H. DE QUIDT, M. see CARRUTHERS, B., 190P The serotonin agonist 8-OH-DPAT elicits DE SARRO, G.B. see CROUCHER, M.J., feeding in non-deprived rats, 374P 137P CUTHBERT, N.J., GARDINER, P.J. & DE WILDT, D.J. & NIJKAMP, F.P. TREVETT, A. Leukotriene-induced Bordetella pertussis vaccine constit- increase in TXA2 generation by guinea- uents cause disturbance of autonomic pig small airways: mechanism of action, receptor functioning within the 102P vardiovascular system of the rat, 87P CUTLER, M.G., MCLAUGHLIN, M. & MOORE, DE WILDT, D.J., FOLKERTS, G., NIJKAMP, M.R. of Effects 8-aminolaevulinic F.P. & VAN HEUVEN-NOLSEN, D. Influence acid in isolated preparations of rabbit of different bacteria and their com- small intestine, 418P ponents on guinea-pig lung (- adren- oceptor function and number, 3P D'ARCY, P.F., MCELNAY, J.C. & SIDAHMED, A.M. Chloroquine-digoxin interaction, 88P DEAN, J.A., FORD, M.G. & LEAKE, L.D. xytryptamine (5-HT) receptors, 34P A systematic study of parameters - - - Subtypes of neuronal 5-hydroxy- defining the response of a neurone tryptamine (5-HT) receptors as (the leech Leydig cell) to exogenously- identified by competitive antagonists, applied amines, 126P 33P DELGADO, C., TAMARGO, J. & TEJERINA, T. - - - The inhibitory effects of The electrophysiological effects of neuronal 5-hydroxytryptamine (5-HT) propafenone on guinea-pig papillary receptor antagonists on experimental muscles, 171P main in humans, 35P DEMPSTER, J. (Introduced by MARSHALL, DOREY, P.G. & WOODRUFF, G.N. Chlor- I.G.) A set of computer programs for diazepoxide enhances the inhibition of electro-physiological analysis of VTA dopaminergic neurones produced by end plate current characteristics, nucleus accumbens stimulation, 301P 459P DOURISH, C.T. see COOPER, S.J., 420P DENNIS, T. see ARBILLA, S., 249P - - - see CURZON, G., 374P DETTMAR, P.W. see BERRIDGE, T.L., 179P DOWNING, O.A., MARRIOTT, J.F. & WILSON, DETTMAR, P.W., KELLY, J. & MACDONALD, A. K.A. Differential effects of vera- Characterisation of -(-adrenoceptor- pamil on hypoxic and recovery con- mediated responses in rat gastric tractions of rat aorta after exposure fundus, 390P to chronic hypoxia, 211P + DEWHURST, D.G. see DAWSON, C., 451P - - - Effect of ouabain and K -free DICKINSON, S.L., see CURZON, G., 25P Krebs' on hypoxic and recovery res- - - - see CURZON, G., 207P ponses of rat aorta to noradrenaline, DIGGORY, G.L. see BUCKETT, W.R., 270P -321P - - - see BUCKETT, W.R., 394P DOXEY, J.C. see BERRIDGE, T.L., 86P DOCHERTY, J.R. An examination of pre- - - - see BERRIDGE, T.L. 179P and postsynaptic --adrenoceptors in DOXEY, J.C., ROACH, A.G., STILLINGS, spontaneously hypertensive rats, 11P M.R., STRACHAN, D.A., VIRDEE, N.K. & DOCHERTY, J.R. & HYLAND, L. Neuro- WELBOURN, A.P. Potent and selective effector transmission through post- I-adrenoceptor antagonists in a series synaptic 2-adrenoceptors in human of 2-substituted analogues of saphenous vein, 362P idazoxan, 181P DOCHERTY, J.R., HYLAND, L. & WARNOCK, P. DREW, G.M. see BULL, D.R., 319P A further examination of inhibitory DRUMMOND, A.H. see BRYDON, L.J., 187P 11-adrenoceptors of rat vas deferens, DRYDEN, W.F. Loss of response to 326P positive inotropic drugs during hiber- - - - Pre- and postsynaptic actions of nation in ground squirrels, 82P Bayer K8644 in the rat vas deferens, DUCE, I.R. see BODEN, P., 221P 213P DUNCAN, G.P. see BROWN, C.M., 416P DODGE, C.J. & MORTON, I.K.M. Use of - - - see CLARKE, B., 365P substance P antagonists in the invest- DUPONT, A.G. see BOGAERT, M.G., 410P igation of non-adrenergic non- DURANT, G.J., GANELLIN, C.R., GRIFFITHS, cholinergic nerve mediators in smooth R., HARVEY, C.A., IFE, R.J., OWEN, muscle preparations, 110P D.A.A., PARSONS, M.E. & SACH, G.S. DODSON, B.A. see BRASWELL, L.M., 30P Sk&F 93944, a potent Hl-receptor DOGGETT, N.S., MOORE, N.A., PULLAR, histamine antagonist with negligible I.A. & TYE, N.C. Behavioural evidence ability to penetrate into the central for mesolimbic dopamine receptor super- nervous sysstem, 232P sensitivity following long term DUVAL, N., HICKS, P.E. & LANGER, S.Z. diazepam treatment, 121P Dopamine stimulates post-synaptic DOMENEY, A.M. see BRADBURY, A.J., 307P (2-adrenoceptors in the femoral but - - - see BRADBURY, A.J., 393P not the renal vascular bed of the - - - see BRADBURY, A.J., 395P anaesthetised dog, 150P - - - see COSTALL, B., 46P - - - Reserpine-resistant responses - - - see COSTALL, B., 257P to nerve stimulation i the cat nictit- - - - see COSTALL, B., 358P ating membrane are due to newly DONATSCH, P., ENGEL, G., RICHARDSON, synthetised transmitter, 406P B.P. & STADLER, P. ICS 205-930: DYE, A.C. see BROWN, C.M., 310P a highly selective and potent antagon- ist at peripheral neuronal 5-hydro- EBENEZER, I. The acquisition of toler- EMSON, P.C. see CARRUTHERS, B., 190P ance to the depressant effect of vaso- ENGEL, G., see DONATSCH, P., 33P pressin on spontaneous motor activity, - - - see DONATSCH, P., 34P 24P - - - see DONATSCH, P., 35P - - - The effect of vasopressin on ENNIS, C. see BLURTON,- P.A., 36P appetite-motivated lever-pressing EPSTEIN, P.M. see CAMERON, H.A. 444P behaviour in rats, 108P EVANS, H., MARSHALL, R.W. & SPRIGGS, T. ECCLESTON, D. see MARSHALL, E.F., L.B. Differences in the effects of 351P uptake-i blockers on responses of EDVINSSON, L., MCCULLOCH, J. & SHARKEY, rat vas defeens to single pulse J. Dopamine receptor subtypes medi- stimulation, 18P ating the dilatation of cerebral pial artioles in situ, 409P FAGE, D. & SCATTON, B. Inhibitory EDWARDS, D.J. see CANE, A.K., 186P influence of J-adrenoceptors on EDWARDS, D.M. & FEELY, J. A model to striatal cholinergic transmission, study enhanced drug elimination during 155P repeated dosing with activated FAIRHURST, G., STANNARD, M. & WYLLIE, charcoal, 178P M.G. Measurement of natriuretic EDWARDS, G. see BRECKENRIDGE, A.M., hormone levels in rodents and man, 275P 366P - see BRECKENRIDGE, A.M., 399P FARMER, J.B. see BROWN, R.A., lOP EGLEN, R.M. see BATES, R.F.L., 157P - - - see BROWN, R.A., 120P - - - see CLAGUE, R.U., 345P FEATHERSTONE, R.L. & MORTON, I.K.M. _ - see CLARKE, B., 437P Interaction of angiotensin II with EGLEN, R.M. & WHITING, R.L. Comparison substance P in the guinea-pig ileum, of activities of muscarinic agonists hlip on rabbit aorta and guinea pig ileum, FEATHERSTONE, R.L., FOSBRAEY, P. & 386P MORTON, I.K.M. A comparison of direct EGLEN, R.M., FRASER, S. & WHITING, and indirect actions of substance P R.L. Assessment of 2-adrenoceptor and other tachykinins in guinea-pig agonist activity in the isolated, ileum longitudinal muscle, 1O9P perfused guinea pig portal vein of e2 FEELY, J. see EDWARDS, D.M., 178P -adrenoceptor antagonists, 165P FEELY, J. & ODUMOSU, A. Factors affect- EKSTR8M, J., LANGER, S.Z. & PIMOULE, ing the aminopyrine breath test, 404P C. Dissociation between chanes in FEKETE, M.I.K. see CROSS, J.A., 458P density of [3H]-QNB binding and super- FENERTY, C.A. & LINDUP, W.E. Binding of sensitivity to methacholine in rat L-trytophan to albumin: Effect of salivary glands, 148P protein concentration and implications EL TAYAR, N., JENNER, P., KILPATRICK, for brain uptake, 151P G.J., MARSDEN, C.D., TESTA, B. & VAN FENIUK, L., KENNEDY, I. & WHELAN, C.J. DE WATERBEEMD, H. Poorly lipophilic A comparison of the actions of leuko- substituted benzamide drugs show en- trienes and FPL 55712 on guinea-pig hanced affinity for the CHAPS solu- fundic strip and guinea-pig ileum, bilised rat striatal dopamine D2 74p receptor, 289P FENIUK, W., HUMPHREY, P.P.A. & WATTS, ELLIOTT, R.C. & KONYA, R.S. The A.D. 5-carboxamido tryptamine - a cardiotoxic action of extract IV potent agonist at 5-hydroxytryptamine from the sea-anemone Telia felina, receptors mediating relaxation, 209P 162P FENN, G.C. see ANDERSON, D.R., 322P ELLIS, C.E. see COLES, D.J., 304P FENN, C.G. & LITTLETON, J.M. Ethanol ELOI, L., GRLNFELD, J.P., MOURA, A.M. inhibits thrombin-stimulated break- & WORCEL, M. Glucocorticoid down of platelet membrane phospho- induced hypertension in rats: ex vivo lipids, 175P effects of RU 38486 on altered ionic FILE, S.E. & FELLOW, S. FG 7142, a fluxes from vascular smooth muscle, j''-carboline, has an anxiogenic action 144P in the social interaction test, 240P EMMS, H. & LEWIS, G.P. The influence of FILLENZ, M., O'NEILL, R.D. & RYAN, E. sex hormones on an experimental model Effcts of the two enantiomers of 3-PPP of thrombosis in the rat, 71P on dopamine release monitored in vivo and on dopamine synthesis measured in vitro, 119P FITZGERALD, R. see BALFOUR, D.J.K., FOY, J.M., SENIOR, J. & ZEKO, R. The 376P effect of experimental diabetes on the FITZSIMMONS, B.J., IRELAND, R.E. & responses of the isolated rat uterus SPEDDING, M. Comparison of the effect to oxytocin and prostaglandins, 330P of lasalocid (X-537A) and enantio FRANCIS, D.M. see BARR, R.M., 99P X-537A on adrenergic nerve function, FRASER, S. see EGLEN, R.M., 165P 161P FREEDMAN, S.B. & MILLER, R.J. Enhance- FLEMINGER, S., HALL, M.D., JENNER, P., ment of voltage-sensitive calcium KELLY, E., KILPATRICK, G., MARSDEN, channels by a novel dihydropyridine, C.D. & RUPNIAK, N.M.J. Lack of 94P dopamine receptor blockade in the FREEDMAN, S.B., MILLER, D.M., MILLER, mesolimbic area during chronic neuro- R.J. & TINDALL, D.R. Interaction of leptic treatment of rats, 346P maitotoxin with voltage sensitive FLEMINGER, S., HALL, M.D., JENNER, P., calcium channels in cultured neuronal KILPATRICK, G., MANN, S., MARSDEN, cells, 260P C.D. & RUPNIAK, N.M.J. Differential FRETTON, P., TOMLINSON, D.R. & TOWNSEND, effects of administration of halperi- J. Prevention of axonal transport dol, sulpiride or clozapine for 12 defects, in vagus and sciatic nerves months on rat striatal function, 288P of diabetic rats, by aldose reductase FLEMINGER, S., JENNER, P. & MARSDEN, inhibition, 265P C.D. Receptor occupation of striatal D -receptors measured using [3H] GADIE, B. see BERRIDGE, T.L., 179P piflutixol binding to inhibit adenyl- GADIE, B., ROACH, A.G. & TULLOCH, I.F. ate cyclase activity, 124P Partial agonism at central and peri- FLETCHER, A. & FORSTER, E.A. (Introduced pheral i.2-adrenoceptors in the rat, by STEPHENS, R.J.) Clonidine does not 367P antagonise seizures induced by intra- GALZIN, A.M. see BENKELFAT, C., 352P venous infusion of leptazol in rodents, - - - see CAVERO, I., 14P 429P GALZIN, A.M., LANGER, S.Z. & PORTIER,A. - - - Proconvulsant actions of selective Effects of substituted tetrahydro-,/ (--adrenoceptor antagonists, 39P -carbolines on 5HT uptake and release FLOCKHART, I.R., see BAKER, S., 49P in rat hypothalamic slices, 350P FOLKERTS, G., see DE WILDT, D.J., 3P GAMBINI, C., MIGNOT, G. & SAVINI, E.C. FOLKERTS, G., NIJKAMP, F.P. & VAN Dopaminergic behaviour in the rabbit HEUVEN-NOLSEN, D. Haemophilus after chronic pretreatmrent by flupen- influenzae, a time-course study for thixol, sulpiride and desipramine, the changes ini,l-adrenoceptor function 23P and number in guinea-pig lung, 5P GANELLIN, C.R. see DURANT, G.J., 232P, FORD, M.G. see DEAN, J.A., 126P GARD, P.R. & HANDLEY, S.L. The effect FORSTER, E.A. see FLETCHER, A., 39P of increased plasma total tryptophan - - - see FLETCHER, A., 429P on plasma non esterified fatty acids FORTUNE, D.H. & IRELAND, S.J. Antagon- in male mice, 164P ism by MDL 72222 of 5-HT-induced GARDINER, P.J. see CUTHBERT, N.J., depolarisations of the rat isolated 102P vagus nerve and superior cervical GARDINER, P.J. & STOCK, D.M. A compara- ganglion, 170P tive study of LTD4 actions on guinea- FOSBRAEY, P. see FEATHERSTONE, R.L., pig airways using the tissue bath and 109P cascade test systems, lOlP FOZARD, J.R. see AZAMI, J., 129P - - - Indomethacin-induced hyper- - - - see BEY, P., 50P reactivity of human small airways to FOZARD, J.R. & RAMAGE, A.G. The effects LTD4, 66P of 8-hydroxy-2-(DI-N-propylamino) GARDINER, S.M. see BENNETT, T., 84P tetralin on the cardiovascular system - - - see BENNETT, T., 217P of the cat: comparison with clonidine, - - - see BENNETT, T., 320P 391P GARDNER, C.R. Do intravenous benzo- FOZARD, J.R., PALFREYMAN, M.G. & diazepines enhance GABA-mediated ZREIKA, M. The comparative pharmac- inhibition of the cerebellum? 302P ology of two selective inhibitors of monoamineoxidase B: deprenyl and MDL 72145, 309P GARNIER, D. & ROULET, M.J. In vitro GRIFFITHS,.R. see DURANT, G.J., 232P ductus arteriosus as a model for GRIFFITHS, R.J. & MOORE, P.K. anti-ischemic drug studies, 407P Effect of uninephrectomy on renal GARRETT, N.J., JENNER, P., MARSDEN, prostanoid biosynthesis in the rat, C.D., REYNOLDS, G.P. & RUPNIAK, 431P N.M.J. [3H]-ketanserin-binding to GROSSET, A. see CAVERO, I., 146P 5-HT2 receptors in rat brain: effects GRUNFELD, J.P. see ELOI, L., 144P of chronic neuroleptic administration, GUEUDET, C., see BIZIERE, K., 51P 342P GULAID, A.A. see BOOBIS, A.R., 89P GEDDES, C. see COMBE, D.M., 415P GUNNING, S.J. see COSTALL, B., 116P GIBSON, A. see BERN, H.A. 104P - - - see COSTALL, B., 325P GIDDINS, R.E. see BRADBURY, A.J., - - - see COSTALL, B., 387P 139P GIEMBYCZ, M.A. & RODGER, I.W. The HAIGH, C.G., KAFY, A.M.L. & LEWIS, D.A. effect of leukotriene D4 on tension Observations of the anti-inflammatory responses and cyclic nucleotide action of putrescine, 283P levels in guinea-pig strips, 231P HALL, J. see BROWN, R.A., 10P GIEMBYCZ, M.A., RODGER, I.W. & SHAHID, HALL, J.C. see BROWN, R.A., 120P M. Forskolin and positive inotro- HALL, M.D. see FLEMINGER, S., 288P pism in the mammalian myocardium, - - - see FLEMINGER, S., 346P 414P HALL, M.T., HAMILTON, C.A., KANE, K.A., GILBERT, D.B. see COOPER, S.J., 258P REID, T.L., RODGER, I.W. & WADSWORTH, GINSBURG, M. see BERN, H.A., 104P R.M. 45Ca uptake in the aorta and GITTOS, M. & SPEEDING, M. Comparison mesenteric artery in rabbits with of cis and trans diclofurime with perinephritis hypertension, 259P verapamil as calcium-antagonists, 81P HALLETT, P. see BRITTAIN, R.T., 377P GOADBY, P. & HARDMAN, P.A. The effects HALLIDAY, J. & WILLIAMS, J.S. Inotropic of the thromboxane synthetase responses to low and high concentrat- inhibitor, UK-37248, on anaphylactic ions of ouabain: frequency dependence bronchoconstriction in guinea pigs, and functional antagonism, 188P 403P HALSEY, M.J., MELDRUM, B.S. & WARDLEY- GOEDERT, M., HUNTER, J.C. & NINKOVIC, SMITH, R. The effect of cis-2, 3- M. Evidence for neurtensin as an piperidine dicarboxylic acid on the inhibitory neurotransmitter in the high pressure neurological syndrome, guinea-pig ileum, 255P 43p GRAHAM, P., HARRIS, J.M. & NELSON, HAMID, S. & WHITTLE, B.J.R. Prosta- D.G. Histamine release from leuco- glandin D2 acts as a 'partial cytes of patients suffering from antagonist' in guinea-pig platelets, caterpillar dermatitis, 167P 96P GRANT, T.L. & MCGRATH, J.C. The HAMILTON, C.A. see HALL, M.T., 259P effects of blood gases and nifedipine HAMILTON, C.A., LESLIE, C., MISHRA, N. on pressor responses to angiotension & REID, J.L. Maturation of x-adreno- II in the pithed rat, 226P ceptors in male and female rabbits, - - - The effects of teprotide on 317P pressor responses to Y.-agonists and HAMMOND, M.D. see CANE, A.K., 186P sympathetic nerve stimulation, 368P HAMON, G., LUSAMVUKU, N.A.T. & WORCEL, GRANT, T.L., MCGRATH, J.C. & O'BRIEN, M. The cellular electrophysiological J.W. The influence of blood cases on effects of nicainoprol on dog isolated J-1 and 2 adrenoceptor-mediated cardiac tissues, comparison with pressor responses in the pithed rat, reference drugs, 79P 216P HANDLEY, S.L. see GARD, P.R., 164P GRASSBY, P.F. see BROADLEY, K.J., HANDLEY, S.L. & MITHANI, S. Effect 224P of drugs acting at Xi-adrenoceptors on - - - see BROADLEY, K.J., 32P Geller-Seifter conflict, 341P GREAVES, M.W. see BARR, R.M., 99P - - - Effects on punished responding GREEN, A.R. see APPLEYARD, M., 248P of drugs at .Q-adrenoceptors, 128P GREEN, P.G. & KITCHEN, I. Di-isopropyl- HANDLEY, S.L. & SINGH, L. GABA modul- fluorophosphate enhances entry of ates the head-twitch induced by L-5- alfentanil into mouse brain, 297P HTP, 340P - - - The effect of v-adrenoceptor agon- HERMAN, A.G., JORDAENS, F.H., MAJCHROWIC ists and antagonists on the head- B.B., VERBEUREN, T.J. & ZONNEKEYN, twitch in male mice, 127P L.L. Effect of-tertatolol on pre- and post-junctional in HARDMAN, P.A see GOADBY, P., 430P ,;-receptors canine HARDY, C.G., HOLGATE, S.T., ROBINSON, blood vessels, 2P C. & TATERSFIELD, A.E. Inhaled HERSOM, A.S. & MACKENZIE, J.E. prostaglandin D2 produces broncho- Comparative cardiotoxicity of idazoxan constriction in man, 194P amitriptyline, mianserin and yohimbine HARLAND, D. see BROWN, M.J. 8P in the rabbit, 318P HARRIS, J.M. see GRAHAM, P. 167P HESSE, I.F.A. & JOHNS, E.C. A compar- HARRISON, N.L. & SIMMONDS, M.A. The ison of the effects of selective antagonism by ketamine of N- (-adrenoceptor agonists on renal methyl-D-aspartate in slices of rat tubular sodium reabsorption in the cerebral cortex, 44P rabbit, 40P HARRON, D.W.G., KOBINGER, W. & LILLIE, HEWICK, D.S., TAVENDALE, R. & WILSON, C. Indoramin; brady-cardia due to S.A. The biliary elimination of prolongation of repolarisation time, indocyanine green and nitrazepam in 312P germfree and conventional rats, 434P HARVEY, A.L., JONES, S.V.P. & MARSHALL, HICKS, P.E. see DUVAL, N., 150P I.G. Disopyramide produces non- - - - see DUVAL, N., 406P competitive voltage-dependent block HICKS, P.E., LANGER, S.Z. & MACRAE, A.D. at the neuromuscular junction, 169P Complex inhibitory effects of 6- HARVEY, C.A. see DURANT, G.J., 232P fluoronoradrenaline on the twitch HATTON, R. see ANGELL, D., 339P response of the rat vas deferens at HAUSER, K., JONES, R.S.G. & OLPE, H-R. different frequencies, 17P The atypical actions of trimipramine HICKS, P.E., LANGER, S.Z. & TIERNEY, C. on the telencephalic projection of Potent antagonism by diltiazem of the rat locus coeruleus, 136P ,X-receptor mediated constriction HAWKES, J.E. & KENNEDY, A.J. The in SHR, but not normotensive rat tail effect of D-penicillamine and copper arteries in vitro, 212P on lymphocyte clustering secretion HILBURN, M.E. see BIRCH, N.J., 158P of immunoglobulin G and responses HILL, S.J. see AL-GADI, M., 278P to interleukin 1, 64P HILLIER, K., JONES, D.B., & PACHECO, S. HAWTHORN, M.H. see BROADLEY, K.J., The action of sulphasalazine, indome- 329P thacin and BW-755C on human peripheral HAYES, A.G. & KELLY, A.J. Opioid blood mononuclear cell activation receptors in the rabbit vas deferens, by PHA, 166P. 57P HINDLEY, S.W., PATERSON, I.A. & ROBERTS, HAYES, A.G., SKINGLE, M. & TYERS, M.B. M.H.T. Microinjection of methyl-,' Antagonism of $-adrenoceptor-mediated -carboline-3-carboxy-late into nucleus antinociception in the rat, 58P raphe dorslis reduces social inter- HAYES, R.J. see CALVETE, J.A. 364P action in the rat, 27P - - - see CALVETE, J.A., 441P HIRST, B.H. see BRUNDISH, D.E., 369P HAYES, R.J., LANDER, J., OATES, N.S. HOBBS, A., PATERSON, I.A. & ROBERTS, & SLOAN, T.P. The effect of ketamine M.H.T. The effects on social inter- on the response to field stimulation action of microinjections of R015- and the uptake of [3H]-noradrenaline 1788 into the nucleus raphe dorsalis by the mouse vas deferens, 298P of the rat, 241P HAYLOR, J. & LOTE, C.J. Is the urinary HOLGATE, S.T. see CHURCH, M.K., 76P excretion of PGE from the rat influen- - - - see CHURCH, M.K., 77P ced by change in urine flow? 381P - - - see CHURCH, M.K., 264P HAYLOR, J., LOTE, C.J. & THEWLES,A. - - - see CHURCH, M.K., 282P The relationship between urine pH - - - see HARDY, C.C., 194P and urinary PGE excretion in the HOLGATE, S.T. & MANN, J.S. Release of conscious rat, 75P adenosine and its metabolotes from HEARSE, D.J., see BUSCHMANS, E., 85P human leukocytes activated with the HEDLEY, D., PERTWEE, R.G. & SUTHERLAND, calcium ionophore A23187, 262P J.F. Involvement of acetylcholine HOLMES, S.W. see COLE, D.J., 304P in the hypothermic response of mice to t69-tetrahydrocannabinol, 423P HOLMES, S.W. & SUGDEN, D. A simple ob- servation test for drug effect on sleep latency in the rat, 453P IFE, R.J. see DURANT, G.J., 232P HOOD, H.T. see PATERSON, J.R., 442P ILES, N.C., MOHAMED, Z., OLD, D.C., HORNBY, E.J. & SKIDMORE, I.F. (Introduced JOHNSON, B.E. & STEVENSON, I.H. by HUMPHREY, P.P.A.) Reductions in The in vitro metabolism of psora- thromboxane B2 production as a con- lens used in photochemotherapy, 443P sequence of thromboxane receptor IRELAND, R.E. see FITZSIMMONS, B.J., blockade in human platelet rich 161P plasma, 432P IRELAND, S.J. see FORTUNE, D.H., 170P HORNER, M.W. see CALDWELL, J., 402P IVERSEN, L.L. see BANSAL, S.J., 425P HORTON, R.C., LOGAN, S.D. & the late IYANIWURA, T.A. see BALFOUR, D.J.K. J.H. WOLSTENCROFT. Actions of pip- 456P eridine on single neurones in the rat - - - see BALFOUR, D.J.K., 457P pons, 197P HORTON, R.W. see BROADHURST, A.B., JACKSON, H.C. & SEWELL, R.D.E. -Effect 448P of the opioid-antagonist ICI 154,129 HORTON, R.W., PRESTWICH, S.A. & SPYROU, on food intake in rats, 296P N.S. Synaptosomal GABA uptake in mice JANSEN, J.D., see BOJANIC, D., 4P susceptible (DBA/2), and resistant JASANI, M.K. see BULLOCK, G.R., 92P (C57 B1/6) to audiogenic seizures, JAYSON, M.I.V. see BULLOCK, G.R., 92Fp 235P JENNER, P. see BOYCE, S., 194P HOUGHTON, E. see CALDWELL, J., 402P - - - see BRADBURY, A.J. , 393P HOULT, J.R.S. see BERRY, C.N., 68P - - - see BRADBURY, A.J., 395P - - - see BERRY, C.N., 69P - - - see EL TAYAR, N., 298P HOWELLS, R.E. see BRECKENRIDGE, A.M., - - - see FLEMINGER, S., 124P 275P - - - see FLEMINGER, S., 288P - - - see BRECKENRIDGE, A.M., 399P - - - see FLEMINGER, S., 346P HOYER, D., REYNOLDS, E.E. & WOLFE, - - - see GARRETT, N.J., 342P B.B. Binding of (1251) IBE2254 to JENNER, P., KELLY, E. & MARSDEN, C.D. .t1-adrenoceptors (.'1R) and 1R [3H]-dopamine uptake into rat sub- activated phosphatidylinositol turn- stantia nigra may involve 5-HT over in intact DDT1 cells, 83P neurones, 333P HUDSON, A.L. see BLACKBURN, T.P., - - - Modulation of [3H]-5HT and 203P [3H]-GABA release from slices of rat HUGGETT, A. see BLAIR, I.A., 67P substantia nigra by dopamine and HUGHES, P.J. see CHURCH, M.K., 76P dopamine agonists, 53P - - - see CHURCH, M.K., 77P JENNER, P., KILPATRICK, G.J. & MARSDEN, HUMPHREY, P.P.A. see BRADLEY, P.B., C.D. CHAPS solubilises D2 but not 210P Dl-binding sites from striatal pre- - - - see BRITTAIN, R.T., 377P parations, 52P - - - see FENIUK, W., 209P JENNER, P. LEIGH, N., MARSDEN, C.D., HUMPHREY, P.P.A. & LUMLEY, P. The MUSCATT, S. & REAVILL, C. Cortical effects of AH 23848, a novel thrombox- lesions modify myoclonus induced ane receptor blocking drug, on plate- by the focal injection of picrotoxin lets and vascular smooth muscle, into striatum or cortex, 142P 378P JENNER, P., LUSCOMBE, G. & MARSDEN, HUMPHRIES, R.G. see BROWN, R.A., lOP C.D. Interaction of indoleamine HUNTER, J. see CARRUTHERS, B., 190P antagonists with 5HT1 receptors in HUNTER, J.C. see GOEDERT, M., 255P guinea-pig brainstem, 123P HUTCHINSON, J.B., NAHORSKI, S.R. & JENNER, P., LUSCOMBE, G., MARSDEN, STRUPISH, J. Simultaneous measurement C.D. & SCHONBAUM, E. Central 5HT of endogenous dopamine and cholecy- mechanisms may mediate 5-hydroxytry- stokinin (CCK) release from rat ptophan-induced hypothermia in guinea striatal slices, 253P pigs but not rats, 426P . HUTSON, P.H. see CURZON, G., 374P JENNER, P., MARSDEN, C.D. & RUPNIAK, HYLAND, L. see DOCHERTY, J.R., 213P N.M.J. Nomifensine induces an - - - see DOCHERTY, J.R., 326P exaggerated stereo-typed response - - - see DOCHERTY, J.R., 362P in rats receiving continuous halo- peridol intake for 20 months, 122P JENNER, P., MARSDEN, C.D. & SIMPSON, KANE, K.A., PARRATT, J.R. & ROTHAUL,A.L. M.D.C. Hypophysectomy enhances the Effects of prazosin and nicergoline ability of haloperidol to induce on normal and mildly depressed sheep striatal dopamine receptor super- purkinje fibre action potentials, sensitivity in the rat, 392P 331P JENNEWEIN, H.M., MIERAU, J., SAXENA, KARIM, A.R. see BIRCH, N.J., 158P P.R. & VERDOUW, P.D. Arteriovenous KASPRZAK, L. see BROWN, R.A. 120P anastomotic constriction and arteri- KEANE, P.E. see CRESPI, F., 452P olar dilatation by BEA 1654, a KEELING, D.J. see BRINE, J.M., 174P putative 5-HT1 agonist, 208P KEHR, W. & STEPHENS, D.N. Further JOHNS, E.J. The effect of acute ad- evidence that central benzodiazepine ministration of diltiazem and receptor ligans may exhibit anxiogenic nifedipine on the function of the properties, 42P denervated rat kidney, 328P KELLY, A.J. see HAYES, A.G., 57P - - - The influence of diltiazem KELLY, E., see BOYCE, S., 194P and nifedipine on the response of see FLEMINGER, S., 346P the rat kidney to modest renal see JENNER, P., 53P nerve stimulation, 261P see JENNER, P., 333P - - - see HESSE, I.F.A., 40P KELLY, J. see DETTMAR, P.W., 390P JOHNSON, B.E. see ILES, N.C., 443P KELLY, M.E. see BRADBURY, A.J., 308P JONES, A.W. see CROUCHER, M.J., 138P see COSTALL, B. 46P KELLY, JONES, B.J. see BROWN, C.L., 236P see COSTALL, B., 358P JONES, D.B. see HILLIER, K., 166P KELLY, M.J., RICHARDSON, W. & SWEETMAN, JONES, H. see BRADLEY, P.B., 195P A.J. Selective protective action JONES, R.L. see ARMSTRONG, R.A., of t-tocopherol on noradrenaline- 72P mediated responses in vascular smooth JONES, R.L., SMITH, G.M. & WILSON, muscle, 417P N.H. The effects of a synthetic KEMMENOE, B.H. see BULLOCK, G.R., 92P prostanoid EP092 on intravascular KEMP, J.A., MARSHALL, G.R. & WOODRUFF, platelet aggregation and broncho- G.N. Quantitative analysis of GABA constriction, lOOP agonists and antagonists using the JONES, R.S.G. see HAUSER, K., 136P rat hippocampal slice preparation, JONES, R.S.G. & OLPE, H-R. Activation 199P of the coeruleocortical pathway KENDALL, D.A. see BROWN, E., 154P reduces neuronal excitation by sub- KENDALL, D.A. & NAHORSKI, S.R. stance P in cingulate cortex, 55P Suppression of 5-HT receptor mediated - - - Aging and the sensitivity of inositol phospholipid breakdown in neurones in the rat cingulate cortex brain by chronic antidepressant to substance P and acetylcholine, treatment, 206P 200P KENDALL-TAYLOR, P. see BRUNDISH, D.E., - - - Lesions of the locus coeruleus 369P increase the sensitivity of cingul- KENNEDY, A.J. see HAWKES, J.E., 64P ate cortical neurones to substance KENNEDY, I. see BRITTAIN, R.T., 377P P, 54P - - - see FENIUK, L., 74P JONES, S.V.P. see HARVEY, A.L., 169P KENNETT, G.A. see CURZON G., 25P JORDAENS, F.H. see HERMAN, A.G., 2P - - - see CURZON, G., 207P JORDAN, C.C. see BAILEY, S.J., 61P KENNY, T. see BRIGHT, J.E., 279P JOSEPH, L., see ANGELO-KHATTAR, M., KEY, B.J., TYERS, M.B & YOUNG, A.M.J. 230P The effects of delta-sleep inducing peptide (DSIP) in relation to opioid KAFY, A.M.L. see HAIGH, C.G., 283P receptors, 294P KAN,J.P. see BIZIERE, K., 51P KILGOUR, C. see BURKE, M.D., 445P KANE, K.A. see HALL, M.T., 259P KILPATRICK, A.T. see ALPS, B.J., 449P KANE, K.A. MORCILLO, E.J., RODGER, - - - see CLAGUE, R.U., 436P I.W. & SHAHID, M. Coronary artery KILPATRICK, G.J. see EL TAYAR, N., occlusion-induced arrhythmias in the 289P anaesthetised rat and myocardial - - - see FLEMINGER, S., 288P levels of cyclic AMP and cyclic GMP, - - - see FLEMINGER, S., 346P 332P - - - see JENNER, P., 52P - - - see BENKELFAT, C., 352P KIM, Y-Y. see CHURCH, M.K., 264P - - - see CAVERO, I., 14P KIRBY, G.C. & MCQUEEN, D.S. Effects - - - see DUVAL, N., 150P of substance P on responses of cat - - - see DUVAL, N., 406P carotid body chemoreceptors to - - - see EKSTROM, J., 148P dopamine, noradrenaline and 5-hydrox- - - - see GALZIN, A.M., 350P 350 ytryptamine, 455P - - - see HICKS, P.E., 17P KIRKPATRICK, K.A., see BRYDON, L.J., - - - see HICKS, P.E., 212P 187P LANGER, S.Z., PIMOULE, C., SCATTON, B. KITCHEN, I. see GREEN, P.G., 297P & SCHOEMAKER, H. Pharmacological KITCHEN, I. & ROWAN, K.M. Comparison characterization of [3H]-cocaine- of the effects of naloxone and ICI binding to rat striata 1 membranes, 154,129 on plasma cortocosterone 48P levels in normal and stressed mice, LANIYONU, A.A., MCCULLOCH, C.R. & 56P POLLOCK, D. The excitatory effect KITCHEN, I., MCDOWELL, J., WILSON, J.M. of morphine in isolated segments of & WINDER, C. Low level lead exposure rat colon, 60P alters the development of morphine LEACH, M.J., MARSDEN, C.M., MILLER, antinociception in the rat, 243P A.A., O'DONNELL, R.A. & WESTON, S.B. KITTERINGHAM, N.R., MAGGS, J.L., NEWBY, Cortical amino acid changes after S. & PARK, B.K. The fate of dini- long term electrical kindling in trophenyl-albumin conjugates in the rats, 447P rat, 405P LEAKE, L.D. see DEAN, J.A.., 126P KOBINGER, W. see HARRON, D.W.G., 312P - - - see LAFI, M.A.K., 145P KONYA, R.S. see ELLIOTT, R.C., 162P LEDGARD, S.E., NIEVES, A.L. & KOSTERLITZ, H.W. see CORBETT, A.D., WOODWARD, D.F. Effect of peptid- 389P oleukotrienes on the cutaneous micr- KOZUKA, T. see BARR, R.M., 99P ovasculature of conscious guinea- KROGSGAARD-LARSEN, P. see BOKISCH, pigs, 233P A.J., 125P LEFEBVRE, R.A. see BOGAERT, M.G., KRUK, Z.L. & STAMFORD, J.A. Measurement 410P of irreversibly oxidised species LEFEVRE-BORG, F. see CAVERO, I., 13P in rat brain using high speed double - - - see CAVERO, I., 14P cycle voltammetry at carbon fibre - - - see CAVERO, I., 146P electrodes, 177P LEIGH, N., see JENNER, P., 142P KUMAR, R., MORRIS, E.A. & STOKERMAN, LEIGHTON, G.E. see DAVIES, J.A., I.P. Chronic administration of 133P morphine motivates learning for food - - - see DAVIES, J.A., 271P rewards in rats, 245P LENNARD, M.S. see CREWE, H.K., 435P LENNON, E.A. & POYSER, N.L. Nor- LAFI, M.A.K. & LEAKE, L.D. Octopamine adrenaline and angiotensin II- actions and its interactions with stimulated release of prostacyclin noradrenaline on the rat vas from the mesenteric arterial bed deferens, 145P of hypertensive rats, 324P LAMB, R.J. & MILLER, A.A. N-methyl- LEONARD, B.E. & O'CONNOR, W.T. d-aspartic acid inhibits spontaneous Effect of isomers on the 6-AZA firing of cerebellar purkinje cells deritave of mianserin on behaviour in vitro, 446P and noradrenaline metabolis in bulb- LAMBERT, J.J. see BALFOUR, D.J.K., ectomised rats, 246P 463P LEOUTSAKOS, A., PEARCE, F.L. & - - - see CAMERON, H.A., 444P THOMPSON, H.L. On the mechanism LANDER, J. see HAYES, R.J., 298P of dextran-induced histamine secret- LANE, A.C. & WALTER, D.S. (Introduced ion from rat peritoneal mast cells, by TULLOCH, I.F.) Sodium ions in- 382P crease the affinity of idazoxan for LEPRAN, I., PARRATT, J.R., SZEKERES, central Al-binding sites labelled by L. & WAINWRIGHT, C.L. Antiarrhyth- [3H]-prazosin, 422P mic effects of a metprolol thrombox- LANGER, S.Z. see ARBILLA, S., 249P ane synthesis inhibitor combination

- see ARBILLA, S., 252P in conscious rats, 225P LESLIE, C. see HAMILTON, C.A., 317P LOWE, K.C., MCNAUGHTON, D.C. & MOORE, LESLIE, R., OSBORNE, N.N., PATEL, S. J.P. Effect of perfluorocarbon & PEARD, A. An immunohisto-chemical emulsion, fluosol-DA, on histamine study to localise histaminergic neur- release from rat peritoneal mast ones in invertebrate and vertebrate cells in vitro, 276P nervous systems, 250P LUMLEY, P. see BRITTAIN, R.T., 377P LEWIS, D.A. see HAIGH, C.G., 282P - - - see HUMPHREY, P.P.A., 378P LEWIS, G.P. see EMMS, H., 71P LUSAMVUKU, N.A.T. see HAMON, G., 79P LIGHTON, C. see BENNETT, G.W., 267P LUSCOMBE, G. see JENNER, P., 123P LILLIE, C. see HARRON, D.W.G., 312P - - - see JENNER, P., 426P LINDUP, W.E. see CLEGG, L.S., 180P LUSCOMBE, G.P. see BUCKETT, W.R., - - - see FENERTY, C.A., 151P 132P LITTLE, H.J. & NUTT, D.J. Benzodia- - - - see BUCKETT,W.R., 306P zepine contragonists cause kindling, - - - see BUCKETT, W.R., 394P 28P - - - see BUCKETT, W.R., 427P LITTLE, H.J., MINCHIN, M.C.W., NUTT, LYLES, G.A. see ARCHER, D.R., 421P D.J. & TAYLOR, S.C. Investigating - - - see BALFOUR, D.J.K., 463P benzodiazepine receptor function - - - see CAMERON, H.A., 444P in vivo using an intravenous infusion LYLES, G.A., OGG, G.C. & STEVENSON, of DMCM, 463P I.H. BPS bookings by the Apple quick LITTLE, H.J., NUTT, D.J. & TAYLOR, S.C. file system, 463P Further studies on benzodiazepine LYNCH, M.A. see LITTLETON, J.M., receptor-mediated kindling, 286P 176P - - - Hypothermic effects of benzodia- zepine agonists, antagonists and MCADAMS, R.P. & WATERFALL, J.P. contragonists, 285P Functional subsensitivity of post- - - - Selective potentiation of the junctional f2-but not (l-adreno- effects of a benzodiazepine contr- ceptors in the dog saphenous vein agonst after chronic flurazepam with reduction in temperature, 412P treatment in mice, 360P MCARDLE, C.A. see BATES, R.F.L., 157P - - - The benzodiazepine antagonist, - - - see BATES, R.F.L., 259P Ro 15-1788, does not alleviate the - - - see BATES, R.F.L., 408P ethanol withdrawal syndrome in rats, - - - see BOARDER, M.R., 363P 357P MCBEAN, D.E. see SKETT, P., 400P LITTLETON, J.M. see ANDERSON, D.R., MCCULLOCH, C.R. see LANIYONU, A.A., 322P 60P - - - see FENN, C.G., 175P MCCULLOCH, J. see ENVINSSON, L., 409P LITTLETON, J.N. & LYNCH, M.A. Altered MCCULLOCH, M.W., RAND, M.J., ROSE, A. catecholamine release by indirect & STORY, D.F. Uptake and release of sympathomimetics from brain slices of 5-hydroxytryptamine by sympathetic ethanol-treated rats, 176P nerve terminals in rat atria, 384P LITTLETON, J.M., MONTAGUE,A. & MCDONALD, A. see DETTMAR, P.W., 390P RAMCHARAN, E. Loss of presynaptic MACDONALD, A.G., MARSHALL, N.R. & adrenoceptor function in rat vas PERTWEE, R.G. The effect of nitrous deferens associated with ethanol oxide on behavioural thermoregulation tolerance, 348P in mice, 424P LIVINGSTON, A., MORRIS, B. & TURNER, J. MCDONALD, I. see BEY, P., 50P The effects of clonidine and xylazine MCDOWELL, J., see KITCHEN, I., 243P on tail flick latency during naloxone MCELNAY, J.C. see D'ARCY P.'F., 88P induced withdrawal in morphine toler- MCGRATH, J.C. Is the "Ca -free" ant rats, 130P -t1-adrenoceptor-mediated response of LLEWELLYN, K.D. see ANDERSON, S., 106P smooth muscle limited to full agon- LODGE, D. see ANIS, N.A., 196P ists?, 344P LOGAN, S.D. see HORTON, R.C., 197P - - - see GRANT, T.L., 216P LOO, H. see BENKELFAT, C., 352P - - - see GRANT, T.L., 226P - - - LORD, J.A.H. see BERRIDGE, T.L., 179P see GRANT, T.L., 368P LOTE, C.J. see HAYLOR, J., 75P - see HAYLOR, J., 381P MCGRATH, J.C., MACLENNAN, S.J., MANN, 205P A.C. & STUART-SMITH, K. Analysis of MARSDEN, C.A. & ROUTLEDGE, C. In vivo the contractile responses of human measurements of DOPAC, 5H1AA and umbilical blood vessels to 5-HT and 5-HT in specific brain regions by oxygen, 290P intracerebral dialysis, 268P MACINTYRE, D.E. see BRYDON, L.J., 187P MARSDEN, C.A. & STOLZ, J.F. Lack of MACKAY,D. Functional interaction bet- effect of chronic antidepressant ween carboachol and various drugs administration on striatal dopamine which relax or contract the isolated autoreceptor sensitivity, 284P trachea of the guinea-pig, 388P MARSDEN, C.D. see BOYCE, S., 194P MCKENZIE, M. see BROWN, C.M., 416P - - - see BRADBURY, A.J., 393P MACKENZIE, J.E. see HERSON, A.S., - - - see BRADBURY, A.J., 395P 318P - - - see EL TAYAR, N., 289P MCKNIGHT, A.T. see CORBETT, A.D., - - - see FLEMINGER, S., 124P 389P - - - see FLEMINGER, S., 288P MCLAUGHLIN, M. see CUTLER, M.G., - - - see FLEMINGER, S., 346P 418P - - - see GARRETT, N.J., 342P MACLENNAN, S.J. see MCGRATH, J.C., - - - see JENNER, P., 52P 290P - - - see JENNER, P., 53P MCLEOD, L.J., PIPER, P.J. & STANTON, - - - see JENNER, P., 122P A.W.B. Leukotrienes C4 and D4 are - - - see JENNER, P., 123P potent constrictors of the porcine - - - see JENNER, P., 142P renal vascular bed, 65P - - -- see JENNER, P., 333P MCMILLAN, R.M. see MASTERS, D.J., 70P - - - see JENNER, P., 392P MCNAMEE, P.M. see DAVIS, E., 440P - - - see JENNER, P., 426P MCNAUGHTON, D. see LOWE, K.C., 276P MARSDEN, C.M. see LEACH, M.J., 447P MCQUEEN, D.S. see KIRBY, G.C., 455P MARSHALL, E.F., TYRER, S.P., ALDERSON, MACRAE, A.D. see HICKS, P.E., 17P E. & ECCLESTON, D. Effects of MAGGS, J.L. see KITTERINGHAM, N.R. fluoxetine in imipramine-binding 405P in vivo and in vitro, 351P MAJCHROWICZ, B.B., see HERMAN, A.G., MARSHALL, G.R. see KEMP, J.A., 199P 2P MARSHALL, I. see ADAMS, M., 316P MALLARKEY, G., MOTION,M.C. & SMITH, MARSHALL, I. see BAKER, S., 49P G.M. Does thromboxane A2 directly MARSHALL, I. & ROBERTS, P.M. Effect of or indirectly stimulate bronchial histamine on bradycardia induced by smooth muscle in guinea-pigs? 439P acetylcholine and vagal stimulation MALLORGA, P., SUGRUE, M.F. & VIADER, in the guinea-pig, 91P M.P. Effect of forskolin on the intra- - - - Histamine inhibition of acetyl- ocular pressure and on the synthesis of choline-induced bradycardia in the cyclic-AMP in the albino rabbit eye, guinea-pig isolated right atrium, 182P 263P MALTA, E., MOLENAAR, P. & RAPER, C. MARSHALL, I.G. see HARVEY, A.L., 169P Structure-affinity and structure- MARSHALL, N.R. see MACDONALD, A.G., efficacy relationships at ,-adreno- 424P ceptor sites, 361P MARSHALL, R.W. see CHEESBROUGH, K.L., MANN, A.C. see MCGRATH, J.C., 290P 336P MANN, J.S. see HOLGATE, S.T., 262P - - - see DAVIES, J.A., 193P MANN, S. see FLEMINGER, S., 288P - - - see EVANS, H., 18P MANNING, A.S. see BUSCEMANS, E., 85P MARSHALL, R.W. & SPRIGGS, T.L.B. MANOURY, Ph. see CAVERO, I., 13P Effects of A-antagonists and (S- - - - see CAVERO, I., 14P methylatp on responses of rat vas MARKHAM, A. see DAVIS, E., 440P deferens to twin pulse field stimula- MARRIOTT, J.F. see DOWNING, O.A., 211P tion, 383P - - - see DOWNING, O.A., 321P MARTIN, D., see BLACKBURN, T.P., 203P MARRS, T.C. see BRIGHT, J.E., 279P MARTIN, I.L. see BROWN, C.L., 236P MARSDEN, C.A. see BENNETT, G.W., 267P MARTIN, K.P. see MARSDEN, C.A., 205P MARSDEN, C.A. & MARTIN, K.F. Changes in MASTERS, D.J. & MCMILLAN, R.M. 5-lipo- 5-HT receptor-mediated behaviour xygenase from human leukocytes, 70P following withdrawal from acute and MATHY, M.J. see DE JONGE, A., 80P chronic amitryptyline administration, MELARANGE, R. & RASHBROOK, L.C. to dopaminergic function in aged Effect of nabumetone on rat gastric rats, 118P mucosal 6-keto-PGF1 production and the - - - The Dl dopamine antagonist relationship to its lack of gastric SCH 23390, but not a D2 antagonist, irritancy, 280P blocks responsivity to the Dl agonist MELDRUM, B.S. see CROUCHER, M.J., 137P R-SK & F 38393, 21P - - - see CROUCHER, M.J., 138P MONTAGUE, A. see LITTLETON, J.M., - - - see HALSEY, M.J., 43P 348P MELY, Y., PALFREYMAN, M.G., SLEIGHT, MOORE, J.P. see LOWE, K.C., 276P A.J. & ZREIKA, M. Selective activat- MOORE, M.R. see CUTLER, M.G., 418P ion of the monoamine oxidase inhibit- MOORE, N.A. see DOGGETT, N.S., 121P ing pro-drug, MDL 72394 by AADC of MOORE, N.A., PULLAR, I.A., RISIUS, central monoamine neurons, 355P F.S. & TYE, N.C. LY141865 induced MICHEL, A.D. see CLARKSON, J.S., 375P hypothermia: a possible D dopamine MICHEL, A.D. & WHITING, R.L. Analysis receptor mediated effect, 266P of ligand binding data using a micro- MOORE, P.K. see GRIFFITHS, R.J., 431P computer, 460P MORATINOS, J., OLMEDILLA, B., DE - - - Binding of [3H]-yohimbine in rat PABLOS, I. & VIGUERAS, M.D. - cerebral cortex, 95P adrenoceptor involvement in catechol- MIERAU, J., see JENNEWEIN, H.M., amine-induced hyperglycaemia in 208P conscious fasted rabbits, 220P MIGNOT, G., see GAMBINI, C., 23P MORCILLO, E.J. see KANE, K.A., 332P MIHALY, G.W. see BRECKENRIDGE, A.M., MORET, C. see BRILEY, M., 353P 275P MORGAN, R.M. Lessonwriter:- A - - - see BRECKENRIDGE, A.M., 399P simple authoring system for the MIKOLAJCZAK, B.B. Possible mechanism production of computer assisted by which polyvalent cations inhibit instruction lessons in pharmacology, eccrine sweating in the rat. 185P 461P MILLER, A.A. see LAMB, R.J., 446P MORLEY, M.J. see BRADSHAW, C.M., 117P - - - see LEACH, M.J., 447P MORONEY, M.-A. see BEATTIE, D.E., MILLER, D.M. see FREEDMAN, S.B., 398P 260P MORRE, M. see CRESPI, F., 452P MILLER, K.W. see BRASWELL, L.M., 30P MORRIS, B. see LIVINGSTON, A., 130P MILLER, R.J. see FREEDMAN, S.B., 94P MORRIS, E.A. see KUMAlR, R., 245P - - - see FREEDMAN, S.B., 260P MORTON, I.K.M. see DODGE, C.J., 110P MILTON, A.S. The effects of ketoprofen, - - - see FEATHERSTONE, R.L., 109P dexamethasone and corticotrophin on - - - see FEATHERSTONE, R.L., l11P the hyperthermic effect of polyin- MOSER, P.C. & REDFERN, P.H. Diurnal osinic-polcytidlic acid, 373P variation in behavioural responses MINCHIN, M.C.W. see LITTLE, H.J., 463P to 5-HT receptor stimulation, 269P MIREYLEES, S.E. see BRAMMER, N.T., MOSS, M.S. see CALDWELL, J., 402P 112P MOTION, M.C. see MALLARKEY, G., 439P MISHRA, N. see HAMILTON, C.A., 317P MOURA, A.M. see ELOI, L., 144P MITCHELL, I.J. see CROSSMAN, A.R. MUSCATT, S. see JENNER, P., 142P 454P MITCHELL, P. see BROWN, F., 305P NAHORSKI, S.R. see BARNETT, D.B., MITCHELL, R. see ANDERSON, R.A., 159P 343P - - - see BARNETT, D.B., 160P MITCHELL, R. & WILSON, L. Selective - - - see BOJANIC, D., 4P effects of GABA on putative subtypes - - - see BROWN, E., 154P of benzodiazepine receptors in rat - - - see HUTCHINSON, J.B., 253P cerebellar and hippocampal membranes, - - - see KENDALL, D.A., 206P 143P NAYLOR, R.J. see BRADBURY, A.J., 307P MITHANI, S. see HANDLEY, S.L., 128P - - - see BRADBURY, A.J., 308P - - - see HANDLEY, S.L., 341P - - - see BRADBURY, A.J., 393P MOHAMED,Z. see ILES, N.C., 443P - - - see BRADBURY, A.J., 305P MOLENAAR, P. see MALTA, E., 361P NAYLOR, R.J. see COSTALL, B., 46P MOLLOY, A.G., O'BOYLE, K.M. & - - - see COSTALL, B., 115P WADDINGTON,J.L. Relationship of - - - see COSTALL, B., 116P spontaneous orofacial dyskinesia - - - see COSTALL, B., 257P - - - see BROWN, R.A., 120P - - - see COSTALL, B., 325P - - - see LEONARD, B.E., 246P - - - see COSTALL, B., 337P O'DONNELL, R.A. see LEACH, M.J., 447P - - - see COSTALL, B., 358P O'HARA, N. see BRODDE, O.E., 6P - - - see COSTALL, B., 387P - - - see BRODDE, O.-E., 173P NEAL, M., see CUNNINGHAM, J., 31P O'NEILL, R.D. see FILLENZ, M., 119P NEDERGAARD, O.A. Pre- and postsynaptic O'SHAUGHNESSY, K.M. see COWEN, P.J., actions of indoramin on isolated 29P artery preparations, 313P OAKLEY, N.R. see BROWN, C.L., 236P - - - see ABRAHAMSEN, J., 327P OATES, N.S. see CALVETE, J.A., 364P NELSON, D.G. see GRAHAM, P., 167P - - - see HAYES, R.J., 298P NEWBY, S. see KITTERINGHAM, N.R., 405P ODUMOSU, A. see FEELY, J., 404P NICHOLLS, J. see ATTERWILL, C.K., 32P OETTINGER, R. see BALFOUR, D.J.K., NIDDAM, R. see ARBILLA, S., 249P 376P NIEVES, A.L. see LEDGARD, S.E., 233P OGG, G.D. see BALFOUR, D.J.K., 463P NIJKAMP, F.P. see DE WILDT, D.J., 3P - - - see LYLES, G.A., 463P - - - see DE WILDT, D.J., 87P OLD, D.C. see ILES, N.C., 443P - - - see FOLKERTS, G., 5P OLMEDILLA, B. see MORATINOS, J., 220P NILSSON, T. see ANGELO-KHATTAR,M., OLPE, H-R. see HAUSER, K., 136P 230P - - - see JONES, R.S.G., 54P NINKOVIC, M. see GOEDERT, M., 255P - - - see JONES, R.S.G., 55P NISHIKAWA, T., SCATTON, B. & SERRANO, - - - see JONES, R.S.G., 200P A. GABAergic inhibition of striatal OLSEN, R.W. & WONG, E.H.F. Modulation serotonergic transmission exerted in of GABA and benzodiazepine receptor the dorsal raphe requires the integ- antagonist binding by barbiturates rity of the habenula, 41P in rat cortical membranes, 237P NISTRI, A. see ARENSON, M.S., 152P ORCHARD, M.A. see BLAIR, I.A., 67P NORMAN, A.B., PRINCE, A.K. & WYLLIE, OSBORNE, N.N. see BENTLEY, A.M., 274P G.L. Stereotyped behaviour and body - - - see LESLIE, R., 250P temperature of rats withdrawn from OWEN, D.A.A., see DURANT, G.J., 232P short term treatments with oxypertine or halperidol, 303P PACHECO, S. see HILLIER, K., 166P NORRIS, A.A. see BLACKHAM, A., 98P PACIOREK, P.M. & SHEPPERSON, N.B. NOTARIANNI, L.J. see BENNETT, P.N., Selectivity of WY 26392 and yohimbine 228P for pre-junctional .x2-adrenoceptors in - - - see BENNETT, P.N., 403P the anaesthetised dog, 12P NUNN, B. see CHAMBERLAIN, P.D., 103P PALACIOS, J.M. see CORTES, R., 202P NUTT, D.J. see ATTERWILL, C.K. 194P PALFREYMAN, M.G. see BEY, P., 50P - - - see COWEN, P.J., 29P - - - see FOZARD, J.R., 309P - - - see LITTLE, H.J., 28P - - - see MELY, Y., 355P - - - see LITTLE, H.J., 285P PALOMO, T. & REID, I.C. Effect of - - - see LITTLE, H.J., 286P oxypertine versus reserpine on - - - see LITTLE, H.J., 357P amphetamine and methylphenidate in- - - - see LITTLE, H.J., 360P duced activity in rats, 247P - - - see LITTLE, H.J., 463P PARK, B.K. see KITTERINGHAM,N.R., 405P O'BOYLE, K.M., see MOLLOY, A.G., 21P PARRATT, J.R. see BALL, H.A., 379P - - - see MOLLOY, A.G., 118P - - - see COKER, S.J., 214P O'BOYLE, K.M. & WADDINGTON, J.L. - - - see COKER, S.J., 380P SK&F 83566 and 83692: Benzazepines - - - see KANE, K.A., 331P with selective and stereospecific - - - see LEPRAN, I., actions at the D1 dopamine receptor, 225P 371P PARSONS, M.E. see DURANT, G.J., 232P O'BOYLE, K.M., PUGH, M. & WADDINGTON, PATEL, D.K. see BENNETT, P.N., 228P J.L. Stereotypy induced by the D2 PATEL, S. see PEARD, A., 250P dopamine agonist RU24213 is blocked PATEL, S. & SLATER, P. Auto-radio- by the D2 antagonist R022-2586 and the graphic localization of serotonin D1 antagonist SCH 23390, 242P receptors in mouse brain, 141P O'BRIEN, J.W. see GRANT, T.L., 216P PATERSON, I.A., see HINDLEY, S.W., 27P O'CONNOR, S.E. see BROWN, R.A., lOP - - - see HOBBS, A., 241P PATERSON, J.R., STEVENSON, I.H., HOOD, PIMOULE, C. see CAVERO, I., 14P H.T. & SKELLERN, C.G. Thyroidal - - - see EKSTROM, J., 148P uptake of radioactivity following the - - - see LANGER, S.Z., 48P administration of 14C 3-methyl-2- PINNOCK, R.D. Actions in putative thiohydantoin to rats, 442P neurotransmitters on adult rat dorsal PATERSON, S.J. see CORBETT, A.D., 389P root ganglion neurones, 189P PATMORE, L. see BROWN, C.M., 416P PIOTROWSKI, W. A method of computer - - - see CLARKE, B., 365P averaging biological responses from - - - see CLARKE, B., 437P chart recordings, 184P - - - see CLARKE,B., 438P PIPER, P.J. see MCLEOD, L.J., 65P PATON, D.M. & WEBSTER, D.R. Relation- PLANT, N.T. see COLLIER, H.O.J., 131P ship of metabolism of adenine nucleo- POAT, J.A. see BRINE, J.M., 174P tides to presynaptic inhibition of POIRIER, M.F. see BENKELFAT, C., 352P transmission in rat vas deferens, POLLOCK, D. see LANIYONU, A.A., 60P 385P POLLOCK, W.K. see BRYDON, L.J., 187P PAZOS, A. see CORTES, R., 202P PORTER, M. see BORKOWSKI, K.R., 16P PEARCE, F.L., see BARRETT, K.E., 90P PORTIER, A. see GALZIN, A.M., 350P - - - see LEOUTSAKOS, A., 382P POYSER, N.L., see LENNON, E.A., 324P PEARD, A. see LESLIE, R., 250P PRESTWICH, S.A. see BROADHURST, A.B., PECK, M.J. & TOWART, R. Effects of 448P nifedipine on relaxation of isolated - - - see HORTON, R.W., 235P guinea-pig trachea induced by PRICE, G.W. see BLACKBURN, T.P., 203P salbutamol, 183P PRINCE, A.K. see ATTERWILL, C.K., 32P PECK, M.J., ROUNDING, H.P. & TOWART, R. - - - see NORMAN, A.B., 303P The effects of nifedipine on antigen- - - - see PEDDER, E.K., 134P induced contraction of sensitised PUGH, M. see O'BOYLE, K.M., 242P guinea-pig isolated treachea, 287P PULLAR, I.A. see DOGGETT, N.S., 121P PEDDER, E.K. & PRICE, A.K. The re- - - - see MOORE, N'.A., 266P action of rat brain choline acetyl- transferase (ChaT) with ethylcholine QUINN, P., see BORKOWSKI, K.R., 20P mustard aziridinium ( ECMA) and pheno- - - - see BORKOWSKI, K.R., 222P xybenzamine (PB), 134P QUINN, P.J., see ARR, S.M., 223P PEESAPATI,V., see ARMSTRONG, 4.A., 72P RAEBURN, D. & RODGER, I.W. Leukotriene PELLOW, S. see FILE, S., 240P D4 does not stimulate 45Ca uptake into PERRY, R.H. see CANDY, J.M., 62P guinea-pig tracheal smooth muscle, - - - see CANDY, J.M., 356P 338P PERTWEE, R.G. see BURKE, M.D., 445P RAMAGE, A.G. see FOZARD, J.R., 391P - - - see HEDLEY, D., 423P RAMAGE, A.G. & TOMLINSON, A. Evidence - - - see MACDONALD, A.G., 424P for a sympathoexcitatory action of PETERS, C.J. see ALABASTER, V.A., 163P -X2-adrenoceptor antagonists, 218P PETERS, J.A. & USHERWOOD, P.N.R. RAMCHARAN, E. see LITTLETON, J.M., Characterisation of a 5-hydroxytrypt- 348P amine receptor mediating depolarisatio RAND, M.J. see COLLETT, A.R., 153P of murine neuroblastoma cells, 419P - - - see MCCULLOCH, M.W., 384P PETRIE, J.C. see BARBER, H.E., 93P RANDALL, K. see BROWN, F., 305P PHILPOT, M.E. & SHEPPERSON, N.B. RAPER, C. see MALTA,E., 361P Cardiovascular effects of WY 26392 RASHBROOK, L.C. see MELARANGE, R., and RX 781094 in anaesthetised cats, 280P 334P REAVILL, C. see BOYCE, S., 194P PIERCE, V.& SHEPPERSON, N.B. Effect of - - - see JENNERi P., 142P 1-adrenoceptor antagonist indoramine REDFERN, P.H. see MOSER, P.C., 269P on baroreceptor reflexes in conscious REID, I.C. see PALOMO, T., 247P rats, 314P REID, J.L. see HALL, M.T., 259P PILCHER, C.W.T. see BROWNE, J.L. - - - see HAMILTON, C.A., 317P 299P REIDEMEISTER, J. Chr., see BRODDE, PILOT, M.A., RITCHIE, H.D., THOMPSON, O-.E., 6P H.H. & ZARA, G.P. Alterations in gastro-intestinal motility associated with erythromycin, 168P REUBI, J.C. Novel selective radioligand - - - see FLEMINGER, S., 346P for one subpopulation of rat cortex - - - ree GARRETT,-N.J., 342P somatostatin receptors, 428P - - - see JENNER, P., 122P REYNOLDS, E.E. see HOYER, D., 83P RYAN, E. see FILLENZ, M., 119P REYNOLDS, G.P. see CARRUTHERS, B., 190P SABATIER, J. see CAVERO, I., 147P - - - see GARRETT, N.J., 342P SACH, G.S. see DURANT, G.J., 232P RICHARDSON, A. see BARNETT, D.B., 159P SAVILLE, V.L. see COLLIS,, M.G., 413P RICHARDSON, B.P. see DONATSCH, P., 33P SAVINI, E.C., see GAMBINI, C., 23P - - - see DONATSCH, P., 34P SAXENA, P.R. see BOLT, G.R. 227P - - - see DONATSCH, P., 35P - - - see JENNEWEIN, H.M., 208P RICHARDSON, W. see KELLY, M.J., 417P SAXENA, P.R. & VERDOUW, P.D. Tissue RICHENS, A. see CHEESBROUGH, K.L., blood flow and arteriovenous shunting 336P in pigs measured with microspheres RISIUS, F.C. see MOORE, N.A., 266P of four different sizes, 219P RITCHIE, H.D. see PILOT, M.A., 168P SCATTON, B. see ARBILLA, S., 249P RIVIERE, J.H. see BACK, D.J., 433P - - - see FAGE, D., 155P ROACH, A.G. see BERRIDGE, T.L., 86P - - - see LANGER, S.Z., 48P - - - see BERRIDGE, T.L., 179P - - - see NISHIKAWA, T., 41P - - - see BERRIDGE, T.L., 315P SCHOEMAKER, H. see BENKELFAT, C., 352P - - - see DOXEY, J.C., 181P - - - see LANGER, S.Z., 48P - - - see GADIE, B., 367P SCHONBAUM, E. see JENNER, P., 426P ROBERTS, A.J. see ANGELL, D., 339P SECHTER, D. see BENKELFAT, C., 352P ROBERTS, F. Measuring the dissociation SEGONZAC, A. see BENKELFAT, C., 352P constant of a partial agonist, 281P SENIOR, J. see FOY, J.M., 330P - - - see BRADLEY, P.B., 195P SENIOR, J. & TROUGHTON, K.M. Modificat- ROBERTS, M.H.T. see HINDLEY, S.W., 27P ion of uterine responses to oestrogen - - - see HOBBS, A., 241P in the rat by thromboxane receptor ROBERTS, P.J. see BUTCHER, S.P., 135P antagonism, 73P - - - see BUTCHER, S.P., 251P SERRANO, A. see NISHIKAWA, T., 41P ROBERTS, P.M. see MARSHALL, I., 91P SEVER, P.S. see CALVETE, J.A., 364P - - - see MARSHALL, I., 263P SEWELL, R.D.E. see JACKSON, H.C., 296P ROBINSON, C. see HARDY, C.C., 194P SHAHID, M. see GIEMBYCZ, M.A., 414P ROBINSON, S.P. see CLARK, E.R., 229P - - - see KANE, K.A., 332P RODGER, I.W. see GIEMBYCZ, M.A., 231P SHARIF, N. Autoradiographic visual- - - - see GIEMBYCZ, M.A., 414P ization and characterisation of brain - - - see HALL, M.T., 259P and spinal TRH receptors, 201P - - - see KANE, K.A., 332P SHARIF, N.A. TRH is endogenous to rat - - - see RAEBURN, D., 338P olfactory bulk-evidence from chemical RODRIGUEZ DEL CAMINO, I.L. & SHARMAN, and surgical lesions, 370P D.F. Metoclopramide-induced stereo- SHARKEY, J. see EDVINSSON, L., 409P typed behaviour in the guinea-pig SHARMAN, D.F., see RODRIGUEZ DEL does not depend on the release of CAMINO, I.L., 22P dopamine in the brain, 22P SHAW, A.M. see BRYDON, L.J., 187P ROGER, A. see BRILEY, M., 401P SHELDRICK, R.L.G. see BRITTAIN, R.T., ROHM, N. see BRODDE, O.-E. 6P 377P ROSE, A. see MCCULLOCH, M.W., 384P SHEPPERSON, N.B. Enhancement by -adre- ROSE, I.C. & STOLERMAN, I.P. Discrim- noceptor agonists of responses media- inative stimulus effects of midazolam ted via -adrenoceptors, 15P in rats, 239P - - - see COWLRICK, I.S., 244P ROTHAUL, A.L. see KANE, K.A., 331P - - - see PACIOREK, P.M., 12P ROTHWELL, N.J. see CROSS, J.A., 458P - - - see PHILPOT, M.E., .334P ROULET, M.J. see GARNIER, D., 407P - - - see PIERCE, V., 314P ROUND, A.A. see AZAMI, J., 129P SHERIDAN, D.J. see BROADLEY, K.J. ROUNDING, H.P. see PECK, M.J., 287P 215P ROUTLEDGE, C. see MARSDEN, C.A., 268P SHERIDAN, R.D. see BRADSHAW, C.M. 47P ROWAN, K.M. see KITCHEN, I., 56P SIBBONS, P.D. see BULLOCK, G.R., 92P ROWAN, M.J. see ANWYL, R., 273P SIDAHMED, A.M. see D'ARCY, P.F., 88P RUNDELL, T. see CANFIELD, P., 156P RUPNIAK, N.M.J. see FLEMINGER, S., 288P SIMMONDS, S.H. & STRANGE, P.G. STEPHENS, R.J. see BILL, D.J., 372P Characterisation of the D dopamine STEVENSON, I.H. see BALFOUR, D.J.K., receptor of bovine anterior pituitary, 463P 114P - - - see ILES, N.C., 443P SIMMONDS, M.A. Interactions of the - - - see LYLES, G.A., 463P benzodiazepine R05-4864 with the - - - see PATERSON, J.R., 442P GABA receptor complex, 198P STILLINGS, M.R. see DOXEY, J.C., 181P - - - see HARRISON, N.L., 44P STOCK, D.M. see GARDINER, P.J., 66P SIMPSON, M.D.C. see JENNER, P., 392P - - - see GARDINER, P.J., 1OlP SINGH,L. see HANDLEY, S.L., 127P STOCK, M.J. see CROSS, J.A., 458P - - - see HANDLEY, S.L., 340P STOLERMAN, I.P. see KUMAR, R., 245P SKELLERN, G.G. see PATERSON, J.R., - - - see ROSE, I.C., 239P 442P STOLZ, J.F. see MARSDEN, C.A., 284P SKETT, P. see BARR, J., 396P STORY, D.F. see COLLETT, A.R., 153P SKETT, P. & MCBEAN, D.E. The use of - - - see MCCULLOCH, M.W., 384P liver cubes in the assessment of phase STRACHAN, A.C. see CLAGUE, R.U., 345P 1 drug metabolism in the rat, 400P STRACHAN, D.A. see BERRIDGE, T.L., 86P SKIDMORE, I.F. see HORNBY, E.J. 432P - - - BERRIDGE, T.L., 315P SKINGLE, M. see CALDERWOOD, A., 347P - - - see DOXEY, J.C., 181P - - - see HAYES, A.G., 58P STRANGE, P.G. see ABBOT, W.M., 113P SLATER, P. see CROSSMAN, A.R., 454P - - - see SIMMONDS, S.H., 114P - - - see PATEL, S., 141P STRUPISH, J. see HUTCHINSON, J.B., SLEIGHT, A.J. see MELY, Y., 355P 253P SLOAN, T.P. see HAYES, R.J., 298P STUART, A.M. see CROSSMAN, A.R., 454P SMIT, G., see DE JONGE, A., 19P STUART-SMITH, K. see MCGRATH, J.C., SMITH, A.D. see APPLEYARD, M., 248P 290P SMITH, C.J. see CANDY, J.M., 356P SUCKLING, C.J. see BANSAL, S.J., 425P SMITH, G.M. see JONES, R.L., lOOP SUGDEN, D. see HOLMES, S.W., 453P - - - see MALLARKEY, G., 439P SUGRUE, M.F. see MALLORGA, P., 182P SMITH, G.W. see BROWN, R.A., lOP SUTCLIFFE, F. see BACK, D.J., 149P - - - see BROWN, R.A., 120P SUTHERLAND, J.F. see HEDLEY, D., 423P SMITH, I.R. see BRINE, J.M., 174P SWEETMAN, A.J. see DAVIS, E., 440P SMITH, J.A. see BRADBURY, A.J., 139P - - - see KELLY, M.J., 417P SMITH, K.J. see BARBER, H.E., 93P SZABADI, E. see BRADSHAW, C.M. 47P SMITH, P.B.W. see CALDWELL, J., 402P - - - see BRADSHAW, C.M., 117P SMITH, R.L. see CALDWELL, J., 402P SZEKERES, L. see LEPRAN, I., 225P SNELL, C.R. see BRUNDISH, D.E., 369P - - - see CANDY, J.M., 311P TABERNER, P.V. see CONNELLY, D.M., SNELL, P.H. see CANDY, J.M., 311P 397P SNOOK, G. see ANDERSON, S., 106P TAMARGO, J. see DELGADO, C., 171P SOUILHAC, J. see BIZIERE, K., 51P TAMARGO, J. & TEJERINA, T. Effect of PY SPARKS, M. see DAVIES, J.A., 193P 108-068, a new calcium antagonist, on SPEDDING M. see GITTOS, M., 81P isolated cardiac preparations, 172P - - - see FITZSIMMONS, B.J., 161P TAN, C.C.W. see COSTALL, B., 337P SPRIGGS, T.L.B. see EVANS, H., 18P TATTERSFIELD, A.E. see HARDY, C.C., - - - see MARSHALL, R.W., 383P 194P SPYROU, N.S. see HORTON, R.W., 235P TAVENDALE, R. see HEWICK, D.S., 323P STADLER, p. see DONATSCH, P., 33P TAYLOR, S.C. see LITTLE, H.J., 285P - - - see DONATSCH, P., 34P - - - see LITTLE, H.J., 286P - - - see DONATSCH, P., 35P - - - see LITTLE, H.J., 357P STAMFORD, J.A. see KRUK, Z.L., 177P - - - see LITTLE, H.J., 360P STANNARD, M. see FAIRHURST, G., 366P - - - see LITTLE, H.J., 463P STANTON, A.W.B. see MCLEOD, L.J., 65P TAYLOR, W.A. see CANE, A.K., 186P STEEL, G. & WHITTLE, B.J.R. Gastric TEJERINA, T. see DELGADO, C., 171P damage induced by topical salicylate - - - see TAMARGO, J., 172P can be potentiated by aspirin or TEMPLETON, D. see ADHAM, N., 323P indomethacin, 78P TESTA, B. see EL TAYER, N., 289P STEINBERG, H. see DAVIES, C., 238P THEWLES, A. see HAYLOR, J., 75P STENGER, A. see BRILEY, M., 300P THOM, S. see CALVETE, J.A., 364P STEPHENS, D.N. see KEHR, W., 42P - - - see CALVETE, J.A., 441P THOMPSON, H. see BARRETT, K.E., 90P USHERWOOD, P.N.R. see BODEN, P., 221P THOMPSON, H.H. see PILOT, M.A., 168P - - - see PETERS, J.A., 419P THOMPSON, H.L. see LEOUTSAKOS, A., 382P VAN DE BERG, G., DE JONGE, A., THOMPSON, J. (Introduced by STEVENSON, THOOLEN, M.J.M.C., TIMMERMANS, P.B.M. I.H.) Patient anthropometric assess- W.M., WILFFERT, B. & VANSWIETEN, P.A. ment and storage utilizing a cheap Post-junctional -adrenoceptor medi- microcomputer system, 462P ated modulation of cardiac sympathetic THOMPSON, J.E. see CANDY, J.M., 62P neurotransmission in rats, 9P THOMPSON, M.A. see CLAY, T.P., 234P VAN DE WATERBEEMD, H. see EL TAYAR, N. THOMSON, D.S. see ARUNDEL, P.A., 192P 289P THOOLEN, M.J.M.C., see DE JONGE, A., VAN HEUVEN-NOLSEN, D. see DE WILDT, 19P D.J., 3P - - - see DE JONGE, A., 80P - - - see FOLKERTS, G., 5P - - - see VAN DE BERG, G., 9P VAN ZWEITEN, P.A., see DE JONGE, A., THULESIUS, 0. see ANGELO-KHATTAR, M., l9P 230P - - - see DE JONGE, A., 80P TIERNEY, C. see HICKS, P.E., 212P - - - see VAN DE BERG, G., 9P TIMMERMANS, P.B.M.W.M., see DE JONGE, VERBEUREN, T.J. see HERMAN, A.G., 2P A., 19P VERDOUW, P.D. see JENNERWEIN, H.M., - - - see DE JONGE, A., 80P 208P - - - see VAN DE BERG, G., 9P - - - see SAXENA, P.R., 219P TINDALL, D.R. see FREEDMAN, S.B., 260P VIADER, M.P. see MALLORGA, P., 182P TJIA, J.F. see BACK, D.J., 149P VIGUERAS, M.D. see MORATINOS, J., 220P TOMLINSON, A. see RAMAGE, A.G., 218P VIRDEE, N.K. see BERRIDGE, T.L., 86P TOMLINSON, D.R. see FRETTON, P., 265P - - - see BERRIDGE, T.L., 179P TOWART, R. see PECK, M.J., 183P - - - see BERRIDGE, T.L., 315P - - - see PECK, M.J., 287P - - - see DOXEY, J.C., 181P TOWNSEND, J. see FRETTON, P., 265P VIRMANI, M.A. see BOAKES, R.J., 256P TREVETT, A. see CUTHBERT, N.J., 102P - - - see BOAKES, R.J., 349P TRICKLEBANK, M.D. Behavioural effects VON UEXKULL, A. see COLLIER, H.O.J., of 8-hydroxy-2-(di-n-propylamino) 131P tetralin, a putative 5-HA receptor agonist, 26P WADDINGTON, J.L. see MOLLOY, A.G., 21P - - - Central 5-HT receptor subtypes - - - see MOLLOY, A.G., 118P and the behavioural responses to 5- - - - see O'BOYLE, K.M., 242P methoxy-N,N-dimethyltryptamine, 204P - - - see O'BOYLE, K.M., 371P - - - Is hyperlocomotion induced by WADSWORTH, R.M. see HALL, M.T. 259P the 5-HT agonist RU25969 mediated WAINWRIGHT, C.L. see LEPRAN, I., 225P by the 5-HT receptor? 140P WALI, F.A. Action and interactions of TRIM, J.L. see COLES, D.J., 304P methohexitone at the smooth muscle- TROUGHTON, K.M. see SENIOR, J., 73P nerve preparation of the rat ileum, TUCKER, J.F. see COLLIER, H.O.J., 131P 63P TUCKER, G.T. see CREWE, H.K., 435P - - - Neuromuscular effects of diazepam. TULLOCH, I.F. see BAKER, S., 49P Interactions with -aminobutyric - - - see BERRIDGE, T.L., 179P acid and methohexitone, 411P - - - see GADIE, B., 367P - - - The effect of angiotensin II at TURKISH, S. see COOPER, S.J., 292P the chick biventer vervicis nerve- TURNER, J. see LIVINGSTON, A., 130P muscle preparation, 107P TURNER, J.D. see BOAKES, R.J., 256P - - - The effects of some local anaes- - - - see BOAKES, R.J., 349P thetics and other drugs on calcium- TYE, N.C. see DOGGETT, N.S., 121P induced luminescence of aequorin, 277P - - - see MOORE, N.A., 266P WALKER, R.J. see BOKISCH, A.J., 125P TYERS, M.B. see CALDERWOOD, A., 347P WALLIS, C.J. see BRITTAIN, R.T., 377P - - - see HAYES, A.G., 58P WALLIS, D.I. see AZAMI, J., 129P - - - see KEY, B.J., 294P WALTER, D.S. see BAKER, S., 49P TYRER, S.P., see MARSHALL, E.F., 351P - - - see LANE, A.C., 422P WARD, S.A. see BRECKENRIDGE, A.M., UNGAR, A. see ALLELY, 7P 399P UNWIN, H.P. see CROSSMAN, A.R., 454P WARDLEY-SMITH, B. see HALSEY, M.J., 43P WARNOCK, P., see DOCHERTY, J.R., 213P - - - see BLURTON, P.A., 36P - - - see DOCHERTY, J.R., 326P - - - see BROADHURST, A.M., 37P WATERFALL, J.F. see MCADAMS, R.P., A WOOD, M.D. & WYLLIE, M.G. The sub- 412P cellular site of action of imipramine, WATKINS, J.C. see CROUCHER, M.J., 38P 138P WOODRUFF, G.N. see BRINE, J.M., 174P WATLING, K.J. see BANSAL, S.J., 425P _ _ - see DOREY, P.G., 310P - - - see BRISTOW, D.R., 35p - - - -see KEMP, J.A., 199P WATTS, A.D. see FENIUK, W., 209P WOODS, A.M. see BLACKHAM, A., 98P WEBSTER, D.R. see PATON, D.M., 385P - - - see BLACKHAM, A., 335P WEIGHTMAN, D.R. see BRUNDISH, D.E., WOODS, H.F. see CREWE, H.K., 435P 369P WOODWARD, D.F. see LEDGARD, S.E., 233P WELBOURN, A.P. see DOXEY, J.C., 181P WORCEL, M. see ELOI, L., 144P WESTON, S.B. see LEACH, M.J., 447P - - - see HAMON, G., 79P WHELAN, C.J. see FENIUK, L., 74P WORLOCK, A.J. see BENNETT, P.N., 403P WHITFORD, C.A. see BRUNDISH, D.E., WORMS, P. see BIZIERE, K., 51P 369P WRIGHT, D.J.M. Opioid antagonists, by WHITING, R.L. see BROWN, C.M., 310P an action on the brain, prevent - - - see BROWN, C.M., 416P endotoxin causing the disappearance - - - see CLAGUE, R.U., 345P of circulating white cells and plate- see CLAGUE, R.U., 436P lets, 293P - - - see CLARKE, B., 365P WYLIE, G.L. see NORMAN, A.B., 303P - - - see CLARKE, B., 437P WYLLIE, M.G. see BEATTIE, D.E., 398P - - - see CLARKSON, J.S., 375P - - - see BLURTON, P., 59P - - - see EGLEN, R.M., 165P - - - see BLURTON, P.A., 36P - - - see EGLEN, R.M., 386P - - - see BROADHURST, A.B., 448P - - - see MICHEL, A.D., 95P - - - see BROADHURST, A.M., 37P - see MICHEL, A.D., 46oP - - - see CROSS, J., 191P WHITTLE, B.J.R. see HAMID, S., 96P - - - see CROSS, J.A., 458P - - - see STEEL, G., 78P - - - see FAIRHURST, G., 366P WILFFERT, B., see DE JONGE, A., 19P - - - see WOOD, M.D., 38P - - - see DE JONGE, A., 80P - - - see VAN DE BERG, G., 9P YOUNG, A. see BROWN, R.A., 120P WILL, S.G. see ARMSTRONG, R.A., 72P YOUNG, A.M.J. see KEY, B.J., 294P WILLIAMS, J.S. see HALLIDAY, J., 188P ZAAGSMA, J. see BOJANIC, D., 4P WILLIAMS, L.C. see BANSAL, S.J., 425P ZARA, G.P. see PILOT, M.A., 168P WILLIAMS, R.H. see BRADLEY, P.B., ZEEKO, R. see FOY, J.M., 330P 210P ZERKOWSKI, H.-R. see BRODDE, O.-E., 6P WILSON, C. Comparison of -adreno- ZONNEKEYN, L.L. see HERMAN, A.G., 2P ceptors in guine-pig, rat and human ZREIKA, M. see BEY, P., 50P atria, 1P - - - see FOZARD, J.R., 309P WILSON, J.F. see ANDERSON, S., 106P - - - see MELY, Y., 355P - - - see CHEESEBROUGH, K.L., 336P WILSON, J.M. see KITCHEN, I., 243P WILSON, K.A. see DOWNING, O.A., 211P - - - see DOWNING, O.A., 321P WILSON, K.L. see COLES, D.J., 304P WILSON, L. see MITCHELL, R., 143P WILSON, N.H. see ARMSTRONG, R.A., 72P WILSON, N.H. see JONES, R.L., lOOP WILSON, S.A. see HEWICK, D.S., 434P WINDER, C., see KITCHEN, I., 243P WINN, M.J. see BENNETT, T., 84P - - - see BENNETT, T., 217P WOLFE, B.B. see HOYER, D., 83P The late J.H. WOLSTENCROFT. see HORTON, R.C., 197P WONG, E.H.F. see OLSEN, R.W., 237P WOOD, M.D. see BLURTON, P., 59P SUBJECT INDEX

Acebutolol stereosomers, 89P Airways, guinea-pig, 1OP, 102P Acetylcholine, 31P, 91P, 196P, 263P Airways, human, 66P Acetylcholine receptor, 30P, 244P, 345P Albumin binding, 151P, Acetylcholinesterase, 248P 180P Adenine nucleotides, 385P Alfentanil, 297P Adenosine, 76P, 77P, 262P, 385P Alfuzosin, 13P, 14P Adenosine 3', 5'-monophosphate, cyclic, Aldose, reductase, 265P 278P Aluminium, 185P Adenosine receptor, 413P Amino acid decarboxylase inhibition, Adenosine triphosphatase, K', 398P 139P Adenosine triphosphatase, Na+,K+, 191P, Amino acid receptors, excitatory,, 251P 398P, 450P Amino acids, 152P, 254P Adenylate cyclase, 6P, 76P, 124P, Amino acids, excitatory, 31P, 196P 182, 359P 2-Amino-4-phosphonobutyrate, 135P, Adipocytes, 4P +251P Adrenal gland, 153P (--)-2-Amino-5-phosphonovaleric acid, Adrenaline, 8P, 20P, 146P, 363P 446P [3H]-adrenaline, 327? Y-Aminobutyric acid, 29P, 41P, 124P, Adrenergic nerve, 20P, 161P 143P, 302P, 243P, 411P Adrenergic systems, 418P Y-Aminobutyric acid agonists, 199P a-Adrenoceptor agonists, 368P 'Y-Aminobutyric acid antagonists, 199P al-Adrenoceptor agonists, 213P Y-iminobutyric acid binding, 448P a2-Adrenoceptor agonists, 15P, 86P, 120P r-Aminobutyric acid receptor, 198P, P-Adrenoceptor agonists, 7P, 127P, 183P 237P, 340P a-Adrenoceptor antagonists, 84P, 165P, 'Y-Aminobutyric acid receptor, 359P 436P 'Y-Aminobutyric acid release, 53P al-Adrenoceptor antagonists, 13P, 14P T-Aminobutyric acid uptake, 235P, 425P a2-Adrenoceptor antagonists, 39P, 86P, a -Aminolaevulinic acid, 418P 165P, 315P, 334P, 448P Aminophenone, 279P P-Adrenoceptor antagonists, 7P, 89P, Aminopyrine breath test, 404P 127P Amitriptyline, 205P al-Adrenoceptor binding sites, central, Amphetamine, 238P, 247P, 249P, 252P 422P d-Amphetamine, 456P, 457P a2-Adrenoceptor partial agonists, 367P Anaesthetics, 424P a-Adrenoceptors, 11P, 40P, 58P, 159P, Anaphylaxis, 99P, 287P, 430P 173P, 181P, 215P, 216P, 217P, 220P, Angiotensin II, 107P, 226P, 319P 316P, 364P, 390P, 412P Antiotensin converting enzyme inhibitor, al-Adrenoceptors, 9P, 15P, 83P, 154P, 339P 326P, 340P, 344P, 375P Anhedonia hypothesis, 117P a2-Adrenoceptors, 12P, 17P, 19P, 49P, Animal observation, 453P 86P, 128P, 150P, 155P, 163P, 179P, Anion transport blockers, 349P 212P, 316P, 318P, 362P, 367P, 372P Anococcygeus muscle, mouse, 104P P-Adrenoceptors, 1P, 2P, 3P? 4P, 5P, Anococcygeus muscle, rat, 344P 6P, 16P, 85P, 160P, 173P, 310P, 361P, Anterior pituitary, 114P 416P Anthropometry, 426P f1-Adrenoceptors, 224P Antiarrhythmic activity, class III, 312P j2-Adrenoceptors, 22P Antiarrhythmic drugs, 79P 1 -Adrenoceptors, blockade, 225P Antibiotic side-effects, 168P 3 -Adrenoceptors, supersensitivity, 329P Anticonvulsants, 29P, 138P, 300P Aequorin, 277P Antidepressants, 206P, 284P, 316P, Affinity, 361P 318P Ageing, 118P, 200P Antihypertensive agents, 13P, 14P AH 23848, 377P, 378P, 379P, 380P Anti-inflammatory agents, 283P, 440P Airway smooth muscle, 183P,231P,287P,338P Anti-ischaemic drugs, 407P Antinociception, 58P, 295P Brain, immature rat, 450P Anxiety, 27P, 128P, 340P Brain, stressed rats, 457P Anxiogenic action, 240P, 241P Brain, rat, 456P Anxiogenic agents, 42P Brain cell culture, 32P Aorta, 386P Brain uptake, 151P Aorta, rabbit, 327P Brainstem, guinea-pig, 123P Aorta, rat, 211P, 321P Brainstem, rat, 195P, 197P Apomorphine, 337P, 410P BRL 20627, 387P Arachodonic acid inhibition, 335P Bronchial smooth muscle, guinea-pig, Arachidonic acid metabolism, 98P, 335P 439P Arrhythmias, 225P, 332P, 380P Bronchoconstriction, 100P Arterial smooth muscle, 144P, 259P Bucindolol, 173P Arteries, human, 364P Bulbectomized rats, 246P Arteries, rabbit isolated, 313P BW-755c, 166P Arteriovenous anastomoses, 219P Ascorbate, 177P Caecum, rat, 69P Aspirin, 228P Calcitonin, 157P, 295P Aspirin-like drugs, 69P Calcitonin gene-related peptide, 295P Atrioventricular block, 147P Calcium, 135P, 146P, 344P, 440P Atrium, guinea-pig, 1P, 263P, 413P Calcium antagonists, 81P, 94P, 172P, Atrium, human, 6P 183P, 185P, 365P Atrium, rat, 1P, 384P Calcium channels, 94P, 260P Atropine, 345P Calcium entry, 438P Audogenic seizures, 235P Calcium entry blockade, 80P, 213P, Autonomic receptor function, 87P 365P, 437P, 444P Autoradiography, 141P, 201P, 202P, Calcium flux, 187P 311P, 454P Calcium ionophore A23187, 262P, 282P Axonal transport, 265P Calcium uptake, 259P, 338P Cannabidiol, 445P Bacteria, 3P Capacity limitation, 228P Barbiturates, 30P, 237P Carbachbl, 356P, 388P Baroreceptor reflexes, 314P fi-Carbolines, 28P, 231P, 240P, 286P Basophils, 77P Cardiac cell culture, 365P Basal forebrain, human, 62P Cardiac cells, human, 416P Battlebro rats, 84P Cardiac mitochondria, 223P Bayer K 8644, 213P Cardiac muscle, guinea-pig and rat, 438P Behaviour, 51P, 118P, 238P, 239P, Cardiac suppressants, 82P 269P, 306P Cardiac sympathetic neurotransmission, Behavioural thermoregulation, 424P 9P Benzamide derivatives, 116P Cardioselective calcium entry blockade, Benzodiazepine antagonists, 357P 437P Benzodiazepine receptors, 42P, 143P, Cardiotoxicity, 162P, 318P 236P, 237P, 300P, 463P Cardiovascular system, cat, 334P, 391P Benzodiazepine withdrawal, 360P Cardiovascular system, rat, 87P Benzodiazepines, 29P, 198P, 239P, 285P, Carotid chemoreceptors, 455P 286P, 302P, 343P, 371P Catechol convulsions, 451P Benzomorphans, 196P Catecholamine release, 153P, 176P Bile, 434P Catecholamines, 306P, 406P, 455P Biventer-cervicis muscle, chick, 107P Caterpillar dermatitis, 167P Blister base, 35P Caudal artery, rat, 210P Blood-brain barrier, 106P Cell infiltration, 98P Blood flow, liver, 93P Central nervous system, 304P Blood gases, 216P, 226P Cerebellar slices, rat, 133P, 271P Blood pressure, 84P, 217P, 320?, 415P Cerebellum, rat, 446P Blood vessels, dog, 2P Cerebral cortex, rat, 95P Blood vessels, pig, 208P Cerebral ischaemia, 449P Bordetella pertussis, 87P Cerebral pial arterioles, 409P Bradycardia, 91P, 263P, 312P Cerebro-spinal fluid, 106P Brain, chick, 174P CHAPS, 52P Brain, gerbil, 449P Charcoal, activated, 178P Chlordiazepoxide, 238P, 301P 3,4-Dihydroxyphenylacetic acid, 268P Chloride, 256P 5,7-Dihydroxytryptamine, 267P Chlorimipramine, 352P Di-isopropylfluorophosphate, 297P 2-Chloroadenosine, 131P Diltiazem, 146P, 147P, 212P, 261P, 328P p-Chlorophenylalanine, 267P 6,7-Dimethoxy-4-ethyl-/S-carboline-3- Chloroquine, 88P carboxylate, 463P Cholecystokinin, 253P Dimethoxyquinazoline, 13P, 14P Choline acetyltransferase, 134P 7,12-Dimethylbenz (a) anthracene, 229P Choline transport, 134P Dinitrophenyl-albumin conjugates, 405P Cholinergic function, 32P Dipeptides, 138P Cholinergic neurones, 62P Disodium croglycate, 156P Cholinergic pathways, 423P Disopyramide, 169P Cholinergic transmission, 155P Dissociated cells, 421P Chromaffin cells, 363P Dissociation constant, 281P Cimetidine, 93P, 278P Diurnal variation, 269P Cinanserin, 271P Dopamine, 22P, 25P, 46P, 51P, 118P, Cingulate cortical neurones, 54P, 55P 121P, 150P, 253P, 308P, 449P Cirazoline, 80P Dopamine, endogenous, 249P Circadian rhythms, 193P Dopamine agonists, 10P, 45P, 120P, 257P Clonidine, 8P, 130P, 372P, 391P, 429P Dopamine antagonists, 258P [3H]-cocaine binding, 48P Dopamine autoreceptors, 284P, 305P Collagen, 432P Dopamine infusion, 257P, 307P Colon, rat, 60P Dopamine neurones, 122P, 301P, 393P, Compound 48/80, 282P 394P, 395P, 427P Computer-assisted instruction, 461P Dopamine receptor binding, 242P Computer averaging, 184P Dopamine receptor solubilization, 52P Computers, 193P Dopamine receptors, 19P, 21P, 113P, Computers, 459P 114P, 115P, 124P, 242P, 252P, 288P, Conditioned behaviour, 245P 280P, 346P, 371P, 392P, 402P, 415P Convulsants, 256P Dopamine release, 119P, 452P Convulsions, 28P, 39P, 248P Dopamine synthesis, 119P Cortex, 142P Dopamine uptake, 48P, 112, 333P Cortical neurones, 47P Dopexamine, 10P Cortical noradrenaline feedback, 49P Dorsal raphe, rat, 41P, 241P Cortical slices, rat, 349P Dorsal root ganglion, rat, 189P Corticosterone, 56P Dosage, 399P Corticotropin, 373P Dothiepin, 270P Cnttaneous microvasculature, 233P Drug metabolism, 400P, 405P, 433P, 443P N6-cyclohexyladenosine, 131P Drug-protein conjugates, 405P Cyclic nucleotides, 231P, 332P Drug toxicity, 405P Cyclo-oxygenase, 78P, 280P Duodenum, rat, 105P Cytochrome P-450, 396P, 445P Dyskinesia, 118P, 358P Dysarhythmia, 146P Data analysis, 460P DRA/2J mice, 254P Efficacy, 361P Debrisoquine, 435P Enalapril, 319P, 339P Delta-sleep inducing peptide, 294P Electrophysiological analysis, 459P 2-Deoxyglucose, 454P End plate current, 459P Deprenyl, 309P Endotoxin, 292P, 379P Depression, 132P Endotoxin shock, 72P Desipramine, 23P, 310P Enzyme inhibition, 433P Dexamethasone, 68P, 373P Enzyme, 149P Dextran, 382P Eosinophils, 186P Diabetes, 265P, 330P EP 092, 72P Diabetogenic mice, 397P Epilepsy, 137P Diacetolol, 89P Erythema, 192P Diazepam, 121P, 354P, 411P, 451P Erythromycin, 168P Diclopfurime, 81P Ethanol, 175P, 322P, 397P Digoxin, 88P Ethanol withdrawal, 357P, 397P Dihydroergocristine, 353P Ether stress, 56P Dihydopyridine, 94P Ethylcholine mustard aziridinium, 134P Etorphine binding, 458P Histamine secretion, 90P, 392P Excitatory amino acids, 44P, 137P Histaminergic neurones, 250P Excitatory amino acid antagonists, 138P Housing density, 299P Excitatory amino acid receptors, 135P HPLC, 275P Exploratory locomotion, 305P Hydrocortisone, 132P, 306P Extraneuronal accumulation, 327P 8-Hydroxy-2-(di-N-propylamine)tetralin, 26P, 374P, 391P Fatty acids, 164P Hydroxyaminopropiophenone, 279P Femoral vasculature, 150P 6-Hydroxydopamine, 157P, 224P FG 7142, 240P, 285P, 360P 5-Hydroxyindoleacetic acid, 268P Fibrin, 92P 3-(3-Hydroxyphenyl) N-n-propylpiperidine, Fitness testing, 462P 45P, 119P 6-Fluoronoradrenaline, 17P 5-Hydroxytryptamine, 25P, 33P, 41P, Fluoxetine, 351P 60P, 133P, 206P, 207P, 208P, 219P, Flupenthixol, 23P 227P, 256P, 268P, 273P, 296P, 354P, Flurazepam, 360P 419P, 456P, 457P Food intake, 296P 5-Hydroxytryptamine agonists, 269P, 374P Forebrain, 308P 5-Hydroxytryptamine depolarization, Forskolin, 85P, 182P, 329P, 414P 129P FPL 52694, 156P 5-Hydroxytryptamine radioimmun6ssay, FPL 55712, 74P 274P FPL 60278, 19P 5-Hydroxytryptamine 1A receptor agonists Frontal cortex, rat, 307P 26P ,'-Funaltrexamine, 389P 5-Hydroxytryptamine receptor antagonists Functional antagonism, 188P 33P, 34P, 35P Fundus, guinea-pig, 74P 5-Hydroxytryptamine receptors, 33P, 123P, 132P, 141P, 170P, 202P, 205P, Gastric acid, 156P 208P, 209P, 270P Gastric erosions, 78P 5-Hydroxytryptamine1 receptors, 140P, Gastric emptying, 116P, 325P 203P Gastric fundus, rat, 390P 5-Hydroxytryptamine A receptors, 204P Gastric irritancy, 280P 5-Hydroxytryptamine2 receptors, 342P Gastric mucosa, pig and rabbit, 398P 5- Hydroxytryptamine release, 53P, Gastric secretion, 337P 349P, 350P, 353P, 384P Gastrointestinal motility, 168P 5-Hydroxytryptamine uptake, 36P, 37P, Germfree rats, 434P 350P, 352P, 384P, 425P Glycol solvents, 303P 5-Hydroxytryptaminergic nerve terminals, Glutamate, 447P 38P Glutamate receptors, 221P 5-Hydroxytryptophan, 272P, 426P Glutamate release, 133P, 271P L-5-hydroxytryptophan, 340P Gonodotropin, 229P Hypercalcaemia, 436P Hyperglycaemia, 220P Haemophilus influenlae, 5P Hyperlocomotion, 140P Haemorrhage, 157P Hypertension, 16P, 144P, 222P, 227P, Haloperidol, 302P, 303P 259P, 324P Head-twitch, 127P, 340P Hypnotics, 453P Heart, chick, 444P Hypophysectomy, 392P Heart, guinea-pig, 85P, 413P Hypothalamus, 116P, 325P Heart failure, 10P Hypothalamus, rat, 350P, 353P Helix aspersa neurones, 125P Hypothermia, 266P, 285P, 329P, 372P, Hepatic drug metabolism, 396P 423P, 426P Hepatic glycogenolysis, 220P Hypoxia, 211P, 321P, 417P Hibernation, 82P High pressure neurological syndrome, 43P ICI 154,129, 296P Hippocampal slice, 199P, 273P ICS 205-930, 34P Histamine, 91P, 174P, 195P, 282P, 41 41LP Idazoxan, 218P, 315P, 422P Histamine Hl-receptor antagonists, 2 32P Idazoxan derivatives, 181P Histamine receptors, 263P, 278P Ileum, 386P Histamine H1 receptors, 441P Ileum, guinea-pig, 255P Histamine release, 76P, 77P, 167P Ileum, rat, 63P 264P, 276P Imipramine, 37P Imipramine binding, 351P, 352P Lung dysfunction, 234P Imminofluorescent histochemical analysis LY141865, 266P 250P Lymphocytes, 64P, 92P Immobilisation, 207P Immune models, 98P Maitoxin, 260P In vivo models, 335P Mast cells, 76P, 90P, 276P, 382P Indirect sympathomimetics, 176P Maze-open field, 376P Indoalmine antagonists, 123P MDL 72145, 50P, 309P Indoleamines, 139P MDL 72222, 34P, 129P, 170P Indomethacin, 230P MDL 72394, 355P Indoramin, 191P, 312P, 313P, 314P Mefloquine, 433P Inflammation, 70P, 92P -Melanocyte-stimulating hormone, 106P Inhibition, 112P, 302P Menstrual cycle, 159P Inositol phospholipids, 187P, 206P Meptazinol, 59P Inotropic response, 1P, 188P Mepyramine, 278P Insect nerve-muscle transmission, 221P Mesolimbic area,rat, 346P Insulin, 397P Mesolimbic system, 121P Interleukin 1, 64P Metabolism, 228P Intestine, rabbit, 418P Metaclopramide, 387P Intracellular recording, 189P Metal ions, 422P Intracerebral dialysis, 268P Methaemoglobin, 279P Intraocular pressure, 182P Methohexitone, 63P, 411P Ion channel block, 169P N-methyl D-aspartate receptors, 44P Ionophore, 161P N-methyl-D-aspartic acid, 446P Isolated rats, 320P Methyl-f-carboline-3-carboxylate, 27P Isoprenaline, 336P 5-Methoxy-N,N-dimethyltryptamine, 204P 1-methyl-4-phenyl-1,2,3,6-tetrahydro- Kainic acid, 142P pyridine, 122P, 393P, 394P, 325P, Ketamine, 44P, 298P 427P Ketanserin, 227P, 342P 3-Methyl-2-thiohydantoin, 442P Ketoprofen, 373P Methylphenidate, 247P Kidney, rabbit, 68P Metoclopramide, 22P, 325P Kidney, rat, 20P, 328P Metoprolol, 434P Kindling, 28P, 286P, 447P Mianserin derivatives, 246P Kinetic analysis, 37P Micro-analysis, 275P Microcomputer, 347, 460P, 462P Lasolocid, 161P Microelectrode, 177P Lead toxicity, 243P Microeletrophoresis, 47P Lectins, 113P Microiontophoresis, 195P Leech Leydig cells, 126P Microspheres, 219P Leptazol, 429P Midazolam, 304P Lessonwriter, 461P Milk intake, 291P Leucocytes, 167P, 262P Minaprine, 51P Leukotriene C4, 65P Monoamine oxidase B, 50P Leukotriene D4, 65P, 66P, 1(01P, 102P, Monoamine oxidase activities, 421P 231P, 338P Monoamine oxidase B inhibition, 309P Leukotrienes, 70P, 74P Monoamine oxidase inhibition, 50P, Lignocaine metabolism, 403P 355P Lipolysis, 4P Monoamine oxidases, 210P Lipophilicity, 289P Mononuclear cell activation, 166P Lipoxygenase, 70P, 440P Morphine, 60P, 245P Lithium absorption, 157P Morphine antinociception, 243P Liver, rat perfused, 403P Morphine tolerant rats, 130P Liver cubes, 400P Motoneurones, 152P Liver microsomes, 435P Motor activity, 395P Local anaesthetics, 277P Muscarinic agonists, 386P Locomotor activity, 193P, 4:20P Muscarinic receptors, 62P Locus coerulus activation, 55P Muscimol, 125P Locus coeruleus lesion, 49P, 54P Muscle relaxants, 137P Lung, guinea-pig, 3P, 5P Myenteric plexus, guinea-pig, 389P Myocardium, guinea-pig, 215P Opioid receptors, 59P, 294P, 299P Myocardium, mammalian, 414P O-Opioid receptors, 296P Myoclonus, 123P, 142P Opioid respiratory depression, 244P Ouabain, 188P, 321P Nabumetone, 280P Oxygen, 290P NADPH-cytochrome P-450 reductase, 396P Oxypertine, 247P, 303P, 415P Naloxone binding, 458P Oxytocic agents, 330P Naltrexone, 245P Natiuretic hormone, 366P Pain, 35P Nerve growth factor, 90P Panuramine, 36P Neuroblatoma cells, mouse, 419P Papillary muscles, 171P Neuroeffector transmission, 362P Paracetamol, 67P Neurogenic vasocontriction, 410P Parasympathetic denervation, 323P Neuroplastic action, 46P Parkinsonism, 122P Neuroleptics, 272P, 288P, 342P, 346P Parotid gland, 323P Neuromuscular junction, 169P Partial agonists, 281P Neuronal accumulation, 327P D-pencillamine, 64P Neuronal preparations, 170P Pentobarbitone, 239P Neuronal sensitivity, 200P Peptidoleukotrienes, 233P Neuropeptides, 104P, 190P Perfluorocarbon, 276P Neurotensin, 46P, 255P Permixon, 401P Neurotransmiss ion, 22P pH, 375P Neurotransmitter, inhibitory, 255P Pharmacokinetics, 399P Neurotransmitters, 189P Pharmacological antagonism, 147P Neutralising capacity, 105P Phase 1 drug metabolism, 400P Neutrophils, 186P H-(D)Phe-Cys-Phe-(D)Trp-Lys-Thr-Cys- Nicainoprol, 79P Thr(ol) see SMS 201-995 Nicardipine, 264P, 437P Phenoxybenzamine, 80P Nicergoline, 331P Phentolamine, 252P Nicotinamide adenine dinucleotide Phenylbutazone metabolism, 402P binding, 311P $-Phenylethylamine, 420P Nicotine, 376P Phenylethylamine derivatives, 112P Nicotinic receptor, 30P Phosphatidylinositol, 83P, 356P Nictitating membrane, cat, 15P, 406P Phosphoinositeides, 154P Nifedipine, 214P, 226P, 261P, 264P, Phototoxicity, 443P 287P, 328P Picrotoxin, 142P Nitrendipine binding, 444P Piflutixol binding, 124P Nitrous oxide, 424P Pigment, 427P Nociception, 299P Pimozide, 117P Nodose ganglion, rabbit, 129P Pineal gland, 139P Non-adrenergic non-cholinergic nerves, Piperidine, 196P l1OP Piperidine dicarboxylic acid, 43P Noradrenaline, 136P, 145P, 363P Pithed normotensive rats, 19P Noradrenaline release, 316P Pituitary gland, rat, 343P Noradrenaline uptake, 298P Plasma, 45P, 164P Nucleus accumbens, 257P, 301P Platelet activation, 187P Nucleus accumbens, mouse, 115P Platelet agregation, 96P, 100P, 103P Nucleus accumbens, rat, 452P Platelet function, 322P Platelet phospholipids, 175P Octopamine, 126P, 145P Platelets, guinea-pig, 96P Oestrogen, 73P Platelets, human, 67P, 159P, 160P Olfactory bulb, rat, 370P 351F, 352P, 431P Ontogenesis, 174P, 243P Population spike, 273P Operant behaviour, 108P, 117P Portal vein, guinea-pig, 165P Opiate antagonists, 291P, 292P, 293P Positive inotropic drugs, 82P Opiate side effects, 347P Post mortem brains, 356P Opiate withdrawal, 131P Potassium channel blockade, 152P Opioid binding sites, 389P Prazosin, 47P, 331P K-Opioid receptor agonists, 57P Prazosin binding, 215P, 375P Opioid receptor antagonists, 56P Pressor responses, 368P Proconvulsant action, 448P Saphenous vein, human, 362P Prolactin, 45P SCH 23390, 21P, 387P Propafenone, 171P Schizophrenia, 190P Propranolol, 97, 223P Sea anemone, 162P Prostacyclin, 69P, 324P Secoverine, 345P Prostaglandin excretion, 381P Seizure threshold, 248P Prostaglandin synthetase, 67P Seizures, 429P Prostaglandin D2, 99P Sex hormones, 71P Prostaglandin E, 75P Single pulse stimulation, 18P Prostaglandin E, 6 oxo-, 431P SK & F 93944, 232P Prostaglandins, 68P, 97P, 358P Skeletal muscle, guinea-pig, Prostanoids, 96P 336P Proteases, 135P Skeletal muscle, rat, 421P Protection, 417P SKF 38393, 21P, 266P Protein synthesis inhibitors, 29P Skin, guinea-pig, 99P Psoralens, 443P Sleep, 197P, 294P Pulmonary inflammation, 186P Sleep latency, 453P Punished responding, 128P, 340P Small intestine, rat, 157P Purification, 113P Smooth muscle, 61P, 83P Purinergic system, 383P Smooth muscle relaxation, 209P Purkinje fibres, 79P, 302P, 331P SMS 201-995, 428P Putrescine, 283P Somatostatin binding sites, 368P PY 108-068, 172P Somatostatin receptors, 428P Pyrazoloquinolinines, 236P Spider venom, 221P Pyrimethamine, 275P, 399P Spinal cord, 201P [3H]-spiperone, 114P Quantification, 192P Social interaction test, 27P [3H]-quinuclidinylbenzilate, 148P, Sodium ions, 289P 323P Sodium reabsorption, 40P Spontaneous activity, 24P Radioligand binding, 38P, 59P, 95P, Spontaneous climbing, 115P 159P, 160P, 458p, 460P Spontaneous locomotion, 308P Ranitidine, 93P Spontaneously hypertensive rats, llP, Raphe nucleus, rats, 203P 97P Rearing, 420P Stereotypy, 22P, 242P, 303P Receptor binding, 454P Stomach, rat, 156P, 288P Receptor mechanisms, 337P Stress, 25P Receptor reserve, 154P Striatum, 155P, 253P, 333P Renal artery, 65P Striatum, rat, 48P, 142P, 358P, 452P Renal nerve, rat, 261P Subcellular fractions, 38P, 191P Renal tubules, 40P Substance P, 54P, 55P, 109P, lllP, Renal vasodilation, 120P 200P, 455P Reperfusion, 214P Substance P antagonists, 11OP, hllP Reserpine, 247P, 249P, 329P, 406P Substance P receptors, pre-synaptic, Reserpine-induced hypothermia, 372P 1O9P Retina, rabbit, 31P Substantia nigra, 53P, 203P, 308P, 333P Ro5-4-4864, 198P Sulphasalazine, 166P Ro 15-1788, 357P Sulpiride, 23P RS-21361, 310P Superoxide anion, 283P RU 24969, 140P Supersensitivity, 148P, 205P, 224P, RU 26988, 144P 272P Ryanodine, 438P Sweating, 185P RX 781094, 8P, 334P Sympathetic function, 339P RX 801074, 179P Sympathetic nerve stimulation, 319P Synaptosomes, 235P Salbutamol, 234P Sympathetic nerves, 384P Salicylates, 78P Salivary glands, 148P Tachykinins, 61P, 1O9P Sali"n calcitonin, 408P Tail arteries, rats, 212P Salt preference, 258P Temperature, 285P, 360P, L:.12P Saphenous vein, dog, 412P Teprotide, 368P Vasoconstriction, 16P Tertatolol, 2P Vasodilation, peripheral and renal, 10P Testerone 5 reductase, 401P Vasodilator, 81P Tetrahydro- -carbolines, 350P Vasopressin, 24P, 108P, 217P, 320P L9-Tetrahydrocannabinol, 423P Ventral prostate, rat, 401P Theophylline, 234P Ventricular fibrillation, 214P Thermoregulation, 424P Verapamil, 81P, 211P Thirst, 292P Veratrine, 447P Thrombin, 175P Voltammetry, 177P Thrombosis, 71P Thromboxane, 73P, 225P Wy 26392, 12P, 218P, 334P Thromboxane A2, 439P Wy 26703, 315P Thromboxane B2, 432P Thromboxane antagonism, 72P, lOOP, Xenobiotics, 434P 377P, 378P, 379P, 380P Xylazine, 130P Thromboxane synthetase inhibition, 430P Thyroid, 450P Yohimbine, 12P 95P, 218P, 315P Thyroid hormone, 32P Thyroid state, 7P Thyroid uptake, 442P Thyrotropin-releasing hormone, 368P, 452P Thyrotropin releasing hormone ireceptors, 201P Thyrotropin releasing hormone irelease, 267P Timolol, 223P (-Tocopherol, 417P Tofisopam, 300P Tolbutamide, 149P Tolerance, 24P Toxicity, 122P Trachea, guinea-pig, 388P Trimipramine, 136P Tryptamine, 210P Tryptophan, 164P L-tryptophan, 151P, 180P Tumours, 229P Twin pulse field stimulation, 383P UK-14,304, 163P UK-37248, 430P Umbilical smooth muscle, human, 290P Uninephrectomy, 431P Uptake inhibitors, 18P, 425P Urine flow, 381P Urine pH, 75P Uteral motility, 230P Uterus, 73P, 330P

Vagal stimulation, 91P Valproic acid, 451P Vas deferens, 161P, 298P Vas deferens, human, 441P Vas deferens, rabbit, 57P Vas deferens, rat, 17P, 18P, 145P, 326P, 383P, 385P Vasoactive intestinal polypeptide, 105P, 359P